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Chromatin organization is at the heart of deciphering gene regulation as it is instructive to 
transcription. Current technological advances in next-generation sequencing approaches 
have offered unprecedented opportunities to interrogate the genomic landscape in multiple 
pathological and clinical presentations. Historically, mutations and alterations at the genomic 
loci of protein-coding genes were thought to be exclusively causal to many human diseases. 
However, the non-coding  genome has emerged as the master regulator of chromatin 
dynamics and transcriptional activity. With cancer increasingly becoming the greatest health 
epidemic of our time, the comprehensive genomic characterization of tumor genotypes has 
become central to current therapeutic approaches. 
Functioning as the basic unit of chromatin organisation, chromatin loops and topologically 
associating domains (TADs) compartmentalize genomic loci and their corresponding 
molecular transcriptional elements in three-dimensional space. Transcription of the human 
genome is proximity-dependent requiring the cooperative engagement of non-coding 
elements and epigenetic modifiers to create permissive topological chromatin contacts and 
structures. The repertoire of chromatin contacts at any given time is regulated by the three-
dimensional structure and organization of the chromatin.  TAD structures are formed and 
maintained by chromatin insulating proteins such as CTCF (CCCTC-binding factor) and multi-
protein complex, cohesin. The dysfunction of which, through mutational and epigenetic 
aberrations, directly impacts a plethora of chromatin contacts and the resultant transcriptional 
profiles within each cell. 
Loops and TADs are formed by the binding of CTCF on the conserved 19 bp CTCF binding 
motif as the chromatin is protruded through the "ring-like" multi-protein complex, cohesin. 
When two convergently oriented and CTCF enriched CTCF-binding sites (CBSs) come into 
contact within the ring, cohesin is thought to "hand-cuff" the chromatin resulting in the 
formation a chromatin loop. These loop structures then serve to compartmentalize and restrict 
the chromatin contacts and their frequency within each loop. Promoter-resident CBSs can also 
function as "docking sites” for tissue- and context-specific enhancers.  
The dysregulation of CTCF binding has been repeatedly demonstrated to directly alter 
chromatin contacts in a vast array of cellular contexts including cancer. Fundamentally, CTCF 
functions as a potent regulator of chromatin contacts, which directly instruct transcriptional 
status. Thus, CTCF binding has become an attractive regulatory target for manipulating the 
topological and transcriptional activity of chromatin. In this study, we sought to identify CBSs 
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with differential, specifically abrogated CTCF enrichment that may be hijacked by oncogenes 
in an attempt to modify transcriptional programmes to favour cancer progression.  
 
To this end, we developed an integrated bioinformatic pipeline to identify promoter-associated 
lower-CTCF enrichment sites (PA-LCes) in colorectal cancer (CRC) cell lines as compared to 
primary colonic tissue from CTCF ChIP-Seq data. With ever-growing catalogues of next-
generation sequencing datasets, including ChIP-Seq, in the public domain, the use of 
ENCODE datasets proved to be an economical option and  added layer of standardization in 
our analysis. Briefly the pipeline developed in this study takes ENCODE ChIP-Seq FASTQ 
files from the NCBI SRA using fastqdump as input files. The FASTQ files undergo a quality 
control and dataset filtration with FASTQC. The filtered datasets are then aligned to the hg38 
human genome and fed back into FASTQC to ensure aligned reads pass quality control 
metrics. The mapped reads are then processed using samtools and duplicate reads are 
marked with the picard markduplicates argument. Narrow peaks are then called from 
processed reads using MACS2 and processed using bedtools. Called peaks then undergo a 
final quality control step using ChIPQCr and are visualized using IGV before undergoing 
differential enrichment analysis. Differential CTCF enrichment analysis between the peaks in 
primary sigmoidal colon cells and CRC cell lines is then conducted using DeSeq2 within 
DiffBind. Lower CTCF enrichment peaks are then used for the discovery of the canonical 
CTCF MA00139.1 motif using homer and compared to similar annotations in the primary 
consensus peakset. The resultant lower CTCF enrichment peaks are then annotated using 
homer and ChiPpeakAnno to determine their genomic locations and extract LCes located 
proximal (<1kb)  to annotated TSS or  promoter regions i.e. PA-LCes.   
 
The PA-LCe discovery pipeline developed in this study is highly robust, resulting in some 
previously validated CBSs  implicated in oncogenesis. Intriguingly, the PA-LCe sites identified 
in this study emanate from bidirectional promoters at oncogenes with differential methylation 
and transcriptional patterns in cancer. Additionally these PA-LCes transcribe antisense 
lncRNAs such as the tumor-suppressive aslncRNA ZNF582-AS1. This data adds to the recent 
body of evidence that suggests that disruption of promoter-associated CBSs leads to 
fluctuations in promoter activity. Recent studies have implicated the requirement of CTCF-
lncRNA complexes at promoter regions in facilitating and regulating CTCF docking on 
chromatin which subsequently influences transcriptional activity. In accordance with this, our 
data suggests that the lncRNAs at PA-LCe loci may be molecular targets for the regulation of 
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CTCF binding and transcriptional activity in CRC. Perturbation of CTCF enrichment at PA-
LCes in CRC result in differential chromatin contacts, epigenetic context and, the 
transcriptional activity of the promoters in which they reside.  As CTCF binding at CBSs sites 
is highly modular, the use of targeted CRISPR-mediated gene-editing and DNA methylation 





 Introduction  
 
Considered the blueprint of human life, the human genome contains the DNA that controls all 
the functions within all cell types in our bodies. Although subsets of these cells are 
morphologically and functionally distinct, the genome in each of the cells is almost identical. 
Conformational and epigenetic features of the genome are responsible for the differential 
regulation of the shared genetic information within each tissue and cell. In almost every 
mammalian cell, the 10 um diameter nucleus houses all the cell’s genomic material in non-
membrane bound compartments. Mammalian DNA consists of 23 pairs of chromosomes per 
cell, with each chromosome spanning 59-249 million base pairs cumulating to a length of 
approximately two meters. The packaging of the cell’s genomic material into the compact 
nuclear volume requires not only a high degree of compaction, but also a system of 
organization that allows any specific region of the genome to be unpacked, accessed and 
repacked, efficiently and without knotting, as and when required. This requires sophisticated 
mechanisms of compaction that also facilitate the accessibility of DNA-relevant machinery for 
fundamental processes such as DNA replication and transcription. Genome organization and 
compaction have been evolutionarily conserved in a highly systematic manner in order to 
retain the functional capacity and interactions within the genome in three-dimensional space. 
 
1.1.1 Chromatin compaction  
In its native state the mammalian genome is organized into complex hierarchical high-order 
structures at multiple scale in three-dimensional nuclear space 1,2. At the lowest scale, the 
DNA double helix is tightly coiled around an octamer of core histone proteins to form a 
nucleosome. Linked by “open” and accessible euchromatic stretches of DNA (compartment B, 
Section 1.1.2), these nucleosomes conform to a structure akin to “beads-on-a-string” (Figure 
1-1). As compaction ensues, these beads amass to form densely folded chromatin. These 
fibres are also organized into relatively open euchromatin (compartment A) and condensed 
heterochromatin (compartment B), based on the post translational modifications of the bound 
histone. Chromatin fibres further fold into ~1Mb sized sub-chromosomal domains which fold 
even further to give rise to a single interphase chromosome (Figure 1-1). This fractal globule 
model, first described by Lieberman-Aiden in 2009, allows for the folding and unfolding of 





Figure 1-1: Genome compaction within the mammalian nucleus.The double stranded DNA helix is tightly 
wrapped around an octamer of histone proteins forming a nucleosome. Nucleosomes and open regions of DNA 
are arranged in a “beads-on-a-string’ structure. Nucleosomes agglomerate to form densely folded chromatin fibres. 
Chromatin fibres further compact into chromatin that further folds into discrete ~1Mb sized sub-chromosome 
territories which compact into a single interphase chromosome. 
 
1.1.2 Chromatin organisation  
At the nuclear scale, chromosomes have been shown to occupy distinct spatial territories or 
domains1,2 within the nucleus (Figure 1-1 and 1-2). The spatial positioning of these 
chromosomes has been correlated to chromosome size and gene density, with small gene-
dense chromosomes occupying the nuclear interior and larger gene-poor chromosomes 
localized at the nuclear periphery in a cell type specific manner4 .  Chromosome domains or 
territories contain megabase-scale compartments of transcriptionally active and inactive 
chromatin, euchromatin (compartment A) and heterochromatin (compartment B) respectively2.  
 
Each territory is segmented to form spatially distinct chromatin sub-domains of up to a few 
megabases in length termed topologically associating domains (TADs), that are enriched with 
high frequency cis or intra-chromosomal contacts (Figure 1-2)3. TAD structures can be 




Figure 1-2: Chromatin organisation. Each chromosome in the nucleus is discretely organized into megabase-
sized chromosome domains or domains. Within each chromosome domain, chromatin is segmented into a hundred 
kilobase sized topologically associating domains (TADs)  enriched with high frequency chromatin contacts. Each 
TAD contains chromosome loops that mediate these chroman contacts. The boundaries TAD and loop structures 
are demarcated, and thought to be formed,  by the enrichment of chromatin insulator CTCF.  
 
B respectively5. Heterochromatic or B compartment TADs are typically associated with the 
nuclear periphery while A compartment TADs are centrally positioned within the nucleus. 
 
Fundamentally, TAD structures serve to constrict functionally related chromatin interactions 
between enhancers and their target genes (Section 1.1.2.3.). These may be up to several 
megabases apart in linear space, however they are brought together in three dimensional 
space within TADS thus facilitating transcriptional regulation5-6. TADs have been described in 
many species, suggesting they represent a highly conserved feature of genome organization 
despite being dynamic structures, particularly throughout development and the cell cycle6. 
These chromatin units define transcriptional regulatory landscapes by compartmentalizing the 
genome and thus are fundamental in the shaping of functional chromatin organization.  
 
Extensive high resolution Hi-C (chromatin conformation capture) (Section 1.2.) maps have 
demonstrated the presence of intervening sequences demarcating TAD boundaries, which 
functionally insulate inter-TAD interactions hampering enhancer activity on off-target 
promoters within neighboring TADs7 (Figure 1-2 and 1-12).  A prominent feature at strongly 
demarcated TAD boundaries is the presence of the conserved CTCF (CCCTC-binding factor) 
binding motif 7. CTCF binding sites (CBSs) have been shown to interact with each other in a 
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highly specific convergent orientation8. CTCF is a DNA-binding protein that plays a role in the 
segmentation and insulation of chromatin9,10 as well the formation of chromatin loops11.  
 
Although enriched for CTCF, chromatin loops and TAD boundaries are also populated by the 
DNA-binding protein complex, cohesin12. Cohesin, a multi-protein ring-structured complex, 
also contributes to the formation of loops and TAD boundary demarcation potentially 
“handcuffing” CTCF-bound CBS pairs13. Currently the mechanisms underlying the formation 
of CTCF/cohesin-bound TAD boundaries are not fully understood. However, some studies 
suggest that together CTCF and cohesin are indispensable for the formation and stabilization 
of TAD boundaries as well as long-range chromatin loops within these domains14. Thus, 
disruptions of chromatin loops and TAD boundaries preventing CTCF and/or cohesin binding, 
results in aberrant chromatin contact formation and subsequent anomalous transcriptomic 
activity, often associated with phenotypic abnormalities15 including oncogenesis16,17 (Section 
1.6.5). Chromatin loops share similar features as TADs, with the exception of size (Figure 1-
2). These are typically short-ranged loops functioning locally, within TADs and spanning less 
than 2 megabases9, although some larger loops exist such as the DXZ4-FIRRE super-loop18. 
Thus,  the current paradigm defines loops and TADs as the basic structural units of multi-scale 
chromatin organization, that are indispensable orchestrators of complex chromatin regulatory 
networks and transcriptional activity. 
 
The degree of chromosome intermingling and physical distances between chromosomes 
within the genome correlates to the level of gene expression. Thus,  chromosomes with similar 
expression levels in are close proximity and/or physical contact in a spatio-temporal manner 
throughout different cells types and states19. These inter-chromosomal contact regions contain 
transcriptionally co-regulated gene clusters that are enriched with active transcriptional 
machinery, including phase-separated condensates containing transcription factors and the 
RNA polymerase II (Pol II) carboxy-terminal domain20. Interestingly, the activity of these 
transcriptional condensates is also governed by a hierarchical order of gene or chromatin 
docking onto RNA polymerase II21. Altogether these observations implicate the four-




1.1.2 Chromatin regulation   
1.1.2.1. Epigenetic markers of chromatin regulation 
1.1.2.1.1 Histone modifications  
Genome-wide mapping of histone modifications, using Chromatin Immuno-Precipitation 
Sequencing (ChIP-Seq) (Section 3.1) has emerged as a powerful method to interrogate and 
characterize the functional consequences of chromatin structure.  Emanating from hundreds 
of ChIP-Seq experiments in multiple cell types and disease phenotypes, a “histone code” 
describing the functionality and repertoire of histone modifications in the regulation of 
chromatin organisation and transcription has emerged. The “histone code” considerably 
extends the information potential of the genetic code, where the combination of histone 
modifications on a particular locus allows for the inference of the type of genomic element, its 
 
 
Figure 1-3: Histone modifications characterize and demarcate functional elements in the human genome. 
Promoters, gene bodies, an enhancer and a boundary element are indicated on a schematic genomic region. 
Active promoters are commonly marked by histone H3 lysine 4 dimethylation (H3K4me2), lysine 4 trimethylation 
(H3K4me3) and histone 2A variant (H2A.Z). Transcribed regions are enriched for histone 3 lysine 36 trimethylation 
(H3K36me3) and lysine 79 dimethylation (H3K79me2). Repressed genes may be located in large domains of 
histone 3 lysine 9 dimethylation (H3K9me2) and/or trimethylation (H3K9me3) or lysine 27 trimethylation 
(H3K27me3). Enhancers are relatively enriched for histone 3 lysine 4 monomethylation (H3K4me1), dimethylation 
(H3K4me2), lysine 27 acetylation (H3K27ac) and the histone acetyltransferase p300. CTCF binds many sites that 
may function as boundary elements, insulators or structural scaffolds. These features of chromatin help organize 
and bookmark the DNA for transcriptional activation/repression as well as distinguish functional elements in the 
large expanse of the genome. RNAPII, RNA polymerase II. 
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transcriptional state and its functionality (reviewed in22) (Figure 1-3). Histone modifications 
function by regulating chromatin accessibility of transcription factors (TFs), directly mediating 
the transcriptional state of the marked chromatin and thus, have emerged as potent predictors 
of transcriptional activity.   
Transcriptional state and functionally is pre-determined by epigenetic marks including histone 
modifications. Determined from thousands of ChIP-Seq experiments over the years, different 
cell types and models, histone modifications have emerged as a powerful predictor of 
transcriptional status. Active promoters, enriched for RNA Pol II, are frequently marked by 
H3K4me2, H3K4me3 and H2A.Z while inactive promoters are enriched for H3K27me3, 
K3K9me3 and DNA methylation (Figure 1-3). Poised promoters, however, are typically 
bookmarked by H3K4me3, H3K27me3 and H2A.Z (Figure 1-3). Similar to promoter regions, 
gene bodies can be active or inactive, marked by H3K9me2 and H3K9me3 at inactive gene 
bodies and H3K36me3 and H3K79me2 at active gene bodies (Figure 1-3).Active enhancers 
are frequently enriched with H3K4me1, H3K4me2, H3K27ac and H2A.Z while inactive 
enhancers are marked by H3K9me2, H3K9me3 and DNA methylation (Figure 1-3).  Thus, 
universally H3K4 mono- and dimethylation, H3K27 acetylation and H3K36 trimethylation are 
markers of active transcription while H3K27 and H3K9 mono- and dimethylation, are markers 
of transcriptional repression.   
 
1.1.2.1.2 Transcription factors  
Transcription factors (TFs) are DBPs that function as “master regulators” of the genomic code. 
TFs bind specific sequence motifs (Section 1.1.2.1.4) on the chromatin to regulate 
transcriptional activity. Once bound on to chromatin, TFs function as “guides” that promote or 
hinder the recruitment of chromatin remodelling and/or transcriptional machinery.  This is more 
readily observed in TFs such as PU.123 that have the ability to bind inaccessible 
heterochromatic or nucleosomal DNA establishing regions of “open” chromatin for 
transcriptional machinery to bind. TFs functioning in this manner have been termed “pioneer 
factors” due to their unique ability to shape the epigenetic landscape of the cell particularly 
during differentiation (reviewed in24). 
 
The expression and functioning of TFs can be ubiquitous or cell-specific, with many TFs 
exhibiting lineage-restricted patters of expression, leading to the establishment and 
maintenance of cell-specific transcriptional programs. Promoter and enhancer sequences 
contain cell-specific combinations of bound TF binding sites/motifs, which govern their spatio-
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temporal transcriptional activity. Thus, the ability of TFs to bind specific DNA sequences alone 
is considered indicative of their ability to regulate transcription(reviewed in25)  
 
1.1.2.1.3 DNA methylation 
DNA methylation involves the enzymatic addition of a methyl (-CH3) group onto the 5’ carbon 
of the pyrimidine ring in the cytosine base by DNA methyltransferases (DNMTs). It has been 
estimated that approximately 3% of cytosines within the human genome are methylated, with 
almost all 5’-methylcytosines occurring in the context of the CG dinucleotide, CpG26. Of these, 
approximately 80% of CpG dinucleotides in the genome are methylated27. Within the genome, 
unmethylated CpG dinucleotides tend to exist in clusters greater than 200 bp in length, known 
as CpG islands (CGIs) as well as in regions with large repetitive sequences such as 
retrotransposons and centromeric repeats26. DNA methylation is reversible,  primarily through 
the oxidation of 5’-mC’s by Ten-eleven translocation (TET) proteins followed by replication-
dependent dilution and/or excision. Furthermore, the absence of DNA methylation 
maintenance proteins also reverses DNA methylation through dilution during replication28.  
 
Human genes frequently contain hypomethylated CGIs at their promoters or first exons. The 
methylation of promotor-associated CGIs inhibits the binding of transcriptional factors and Pol 
II resulting in the transcriptional repression of said promoter. Furthermore,  5’-mCs can 
function as docking sites for methylation-dependent DNA binding proteins (DBPs) such as 
methyl-CpG-binding domain proteins, MBD1, MBD2, MBD3 and Mecp2, which bookmark the 
chromatin for transcriptional repression by histone deacetylases, polycomb proteins and 
chromatin remodelling complexes29.  Aberrant methylation at gene promoters is a ubiquitous 
feature of  oncogenesis. In many cancers, the promoters of tumor suppressor genes tend to 
be silenced by CGI hypermethylation (Section 1.3.3) while CGI hypomethylation tends to 
occur at repetitive regions of the genome promoting chromosomal instability. Altogether 
chromatin methylation functions a “bookmark” for transcriptional regulation and 
simultaneously maintains the structural integrity of the genome. 
 
1.1.2.1.4 Sequence motifs 
The regulation of transcriptional machinery on the chromatin is a multi-faceted molecular 
process governed by;  DNA methylation (Section 1.1.2.1.2.), histone modifications (Section 
1.1.2.1.1.), enhancer interactions (Section 1.1.2.3.), transcription factor binding (Section 
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1.1.2.1.2), co-factor binding, enhancer RNAs (eRNAs) (Section 1.1.2.3.2.) and long non-
coding RNAs (lncRNAs) (Section 1.1.2.2.). Each of these processes relies, at least in part, 
on the existence of regulatory sequences or motifs encoded on the bound chromatin. 
Sequence motifs are broadly classified as short, non-coding, recurring and conserved 
nucleotide patterns in the DNA sequence for which one or more DBPs, such as TFs, bind with 
a high affinity. These sequences are typically displayed as sequence logos which represent 
an underlying “position weight matrix” (PWM), which is the relative preference of the TF for 
each base at the binding site/motif. Inevitably, variations or mutations,  in the nucleotides 
within a sequence motif directly affects the binding affinity of the DBP or TF on the chromatin, 
as does mutating the TF itself. This genomic variation has been frequently associated with 
heritable or acquired disease states including cancer which are catalogued in several large-
scale databases including the NHGRI-EBI GWAS catalogue30.  
 
1.1.2.2. Long non-coding RNAs regulate chromatin organisation and functioning  
Simply defined as the transcribed yet untranslated component of the genomic code, non-
coding RNAs (ncRNAs) have been classified by base pair length, genomic origin and their 
functional mechanisms. Representing approximately 70% of the non-coding genome, 
lncRNAs are described as ncRNA’s over 200 nucleotides in length. This size threshold is 
primarily employed to distinguish lncRNAs from smaller ncRNAs such as micro-RNAs 
(miRNAs), transfer RNAs (tRNAs) and piwi-interacting RNAs (piRNAs). LncRNAs are 
classified based on their genomic, epigenomic, tissue and cellular contexts as well as their 
molecular mechanisms. In the past decade, lncRNAs have been consistently shown to fine-
tune transcriptional, translational and post-translational activity. In the context of transcription, 
lncRNA’s typically regulate specific gene targets by altering their epigenetic marks. While the 
post-transcriptional activities of lncRNAs result in controlling the localization and abundance 
of their protein targets.  
 
1.1.2.2.1. Genomic classifications of lncRNAs 
The genomic classification of lncRNA’s is based on the characteristics of their genomic loc i 
(Figure 1-4). Long intergenic RNAs (lincRNAs) are transcribed, as the name suggests, from 
the intervening non-coding portions of the genome between protein coding genes. This class 
of lncRNAs includes a class of lincRNAs transcribed from enhancer regions (Section 1.1.2.3) 
termed enhancer RNAs (eRNAs). Antisense lncRNA’s (aslncRNAs) are transcribed from the 
opposite strand, and typically in the opposite direction, of a known protein coding gene. These 
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lncRNAs may or may not overlap, at least in part, with annotated sense genes. Intronic 
lncRNAs are derived from the introns of protein-coding genes either in the sense or antisense 
direction (Figure 1-4).  
 
 
Figure 1-4: Genomic characteristics of lncRNAs. Intergenic lncRNAs are transcribed from non-coding 
sequences intervening protein coding regions. Antisense lncRNAs are transcribed from the opposite strand of 
protein coding genes. Intronic lncRNAs emanate from the introns of protein coding genes, these can be sense or 
antisense. Bidirectional lncRNAs are transcribed either “head-to-head” or “tail-to-tail” approximately 1kb away from 
protein coding genes. Sense overlapping lncRNAs overlap protein coding regions either upstream from promoter 
regions, within exons or at 3’UTR loci31. 
 
Bidirectional lncRNAs are transcribed “head-to-head” or “tail-to-tail” with protein coding genes 
within <2 kb. “Head-to-head” lncRNAs transcribed from the same promoter as their proximal 
protein-coding gene, are also known as promoter-associated lncRNAs (PA-lncRNAs). 
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Bidirectional lncRNAs include promoter-derived or -associated lncRNAs  (pa-lncRNAs) that 
overlap proximal protein coding promoters either in the sense or antisense direction within 1 
kb from protein-coding genes, suggesting these lncRNAs and messenger (mRNAs) are 
transcribed from the same promoter and potentially by the same transcriptional machinery. 
Sense-overlapping lncRNAs are considered transcript variants of annotated genes yet are not 
translated either due to a lack of substantial open reading frames (ORFs), retained introns, or 
are degraded by nonsense mediated decay (NMD). Within this class there are promoter-
derived/upstream lncRNAs, multi-exonic sense lncRNAs as well as 3’ untranslated region 
(UTR)-derived lncRNAs. (Figure 1-4). Detailed intricacies of lncRNA definitions are reviewed 
elsewhere31–33.  
 
1.1.2.2.2. Molecular mechanisms of  lncRNAs 
As more lncRNAs are catalogued and functionally characterised, the repertoire of 
mechanisms by which they regulate their target genes is being refined. Currently, based on 
their mode of action, lncRNAs are classified as ‘decoys’, ‘sponges’, ‘scaffolds’, ‘guides’ and  
 
 
Figure 1-5: Molecular mechanisms of lncRNAs. a. Enhancer-derived RNAs are short RNAs transcribed from 
regulatory enhancer regions. eRNAs bind to Mediator, a multiprotein complex, to elicit chromatin looping and long-
range chromatin contacts with a parental enhancer and target gene promoters, leading to the activation target 
genes. b. Scaffold lncRNAs function by binding to chromatin modifiers, transcriptional and/or repressive factors 
within a single complex, resulting in DNA binding at target gene promoters. c. Sponge lncRNAs function as 
molecular ‘sinks’ for miRNAs and/or mRNAs to regulate translation and/ or inhibit the formation of RNP complexes. 
d. Decoy lncRNAs function as ‘sponges’ for transcription factors and chromatin modifiers, titrating them away from 




‘enhancer lncRNAs”. Decoy lncRNA’s regulate gene expression by titrating DBPs such as TFs, 
away from chromatin. Decoy lncRNAs can also function as molecular ‘sponges’ or 
‘sinks’ ,binding miRNAs in order to prevent RNAi (RNA inhibition) thus increasing the 
abundance of the mRNA targeted by the miRNA. Inversely, lncRNA’s can ‘guide’ the proteins 
they bind to specific DNA or RNA targets.  
 
LncRNAs can also function as molecular ‘scaffolds’ or ‘docks’ for one or more DNA-protein 
and protein-protein interactions. LncRNAs transcribed from enhancer regions (Section 
1.1.2.3) can function as eRNAs guiding chromosomal looping to exert cis gene regulatory 
effects (Section 1.1.2.3.2). eRNAs are transcribed from enhancer regions allowing them to 
activate genes independent of distance or local genetic context32,35. Frequently at the heart of 
each of the aforementioned molecular mechanisms exhibited by lncRNAs is transcriptional 
regulation34 (Figure 1-5). 
 
1.1.2.3. Enhancer contacts and activity 
Enhancers were first described in 1981 when a tandem 72 bp non-coding genomic sequence, 
independent of its sequence, orientation or its physical distance from the gene, had the ability 
to drastically increase the expression of its target gene36. This regulatory mechanism has since 
been a defining feature for transcriptional enhancers. Enhancer functionality is governed by 
clusters of DNA sequences enriched in TF binding sites, which are occupied by their 
respective transcriptional activating machinery and histone modifications. Enhancer regions 
can range from tens of bases to tens of megabases in length, the later appropriately defined 
as “super enhancers”.  Enhancers assemble these activating factors into close proximity to 
their target promoters via enhancer-promoter contacts. This increases the probability and/or 
the rate of transcription, generally in cis, and sometimes over great distances by altering 
chromatin states and the activity of transcriptional machinery at contacting promoters 
(reviewed in37–40). Thus, enhancers are potent contact-dependent transcriptional activators.  
However, whether enhancer-promoter contacts are predictive of transcriptional activation and 
how enhancer-containing loops govern transcription  the three dimensional context of nuclear 
architecture is still enigmatic.   
It would appear enhancers make physical contacts with their target promoters to facilitate the 
docking of transcriptional machinery, though contrary evidence has been demonstrated41,42. 
The absolute requirement for enhancer-promoter contacts in fine-tuning of transcriptional 
regulation has been highly documented by the Blobel group in the globin locus control region 
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(LCR) and its promoter targets. The  LCR region activates a distinct glass of globin genes in 
a stage-specific manner throughout erythroid development. By rewiring chromatin contacts, 
using specific transcription activator-like effector nuclease (TALEN)-mediated tethering of 
non-target promoters onto the LCR enhancer, the LCR region was shown to function as a 
potent sequence-independent transcriptional enhancer43,44. This locus provides the most 
compelling and comprehensive evidence to date, supporting the absolute requirement of 
enhancer-promoter contacts for precise transcriptional regulation. With the advances in 
chromatin conformation capture (3C)-derived techniques45 (Section 1.3.) including base pair 
resolution techniques ChIA-Pet24 and Capture-C46, several studies have supported this 
paradigm culminating in the creation of several databases and genome browsers with 
annotated promoter-enhancer contacts in multiple tissues and linked to several diseases47–50.  
 
1.1.2.3.1 Epigenetic signatures of enhancer regions  
Depending on their epigenetic marks, enhancers can be transcriptionally active, inactive or 
poised (Figure 1-3). Inactive enhancers are associated with repressive marks like H3K27me1, 
PPRC or DNA methylation (Figure 1-3). Poised enhancers, although devoid of nucleosomes, 
are enriched with the H3K4me1 mark. Active or eRNA-producing enhancers are characterized 
by H3K4me1, H3K27ac enrichment (Figure 1-3)51.  Active enhancers are highly correlated 
with the formation of enhancer-promoter contacts. Transcription factor binding, and 
subsequent histone bookmarks, facilitate docking of transcriptional machinery, along the 
enhancer locus. As observed in promoters, the docking of transcription factors on enhancers 
can be cooperative and/or sequential. Enhancers can then “bring along” transcription factors 
into close proximity to their target promoters thus, acting as potent transcriptional activators.  
 
1.1.2.3.2 Enhancer RNAs 
The accumulation of transcriptionally permissive factors, such as TFs, on enhancer regions 
makes them highly susceptible to transcriptional activation. Thus, it is not surprising that 
enhancers are pervasively transcribed into typically short ncRNAs, termed enhancer RNAs 
(eRNAs)52,53. eRNAs are currently defined as  capped,  unspliced, non-polyadenylated,  cis-
acting non-coding RNAs with a median length of 350 nucleotides.   What is intriguing, is that 
eRNAs shave emerged as potent gene regulators as well. Early studies have linked eRNA 
activity to their interaction with Mediator, a protein complex that physically “bends” the 
chromatin to facilitate the formation of enhancer-promoter contacts35.  Indeed, multiple 
extragenic transcripts have been found within the classic LCR enhancer.  Intriguingly, these 
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short transcripts, correlating with LCR functionality are expressed in a cell type or 
differentiation stage specific manner43. However, whether enhancer functionality is exclusively 
governed by the act of transcription, the presence of the eRNA transcripts, or some 
combination of both, is yet to be determined.  
To date, the transcription of eRNAs has been detected in response to various stimuli in 
multiple phenotypes with the FANTOM5 consortium’s latest estimation of human eRNA-
producing enhancers currently at 65 00054.  Notably, eRNAs are typically transcribed at very 
low levels averaging less than one transcript per cell and as such can only be detected by 
highly sensitive assays such as 5’-Global run-on (GRO)-Seq Cap Analysis Gene expression 
(CAGE)-based sequencing and/or Tyramide Signal Amplification (TSA)-Fluorescence In-Situ 
Hybridization (FISH) microscopy.   Attempts to deconvolute eRNA mechanisms have been 
made, however the results have been varied. A prevailing theme in eRNA functionality, 
demonstrated by knockdown or knockin experiments, is that eRNAs  are potent transcriptional 
activators that enhance transcription in an expression- and localization- dependent manner. 
Whether eRNAs, like lncRNAs, can function independently from their parental enhancers 
remains enigmatic.  
 
With similar epigenetic marks, sequence motifs and transcriptional activity; enhancers and 
promoters share the ability to integrate spatiotemporal cues in order to co-ordinate tissue-
specific gene expression through the expression and binding of tissue specific TFs (Figure 1-
3). Coupled to that, bidirectional promoters have been shown to function as strong 
transcriptional enhancers. Bidirectional transcription has become a characteristic feature of 
active promoters as well as enhancers55,56.  Recently, a genome-wide characterization of 
mouse and human promoters revealed that gene promoters, including FAF2, CSDE1 and 
TAGLN2, regulate the expression of several distal genes in an enhancer-like manner57.  
Conversely, intragenic enhancers were shown to act as alternative, tissue-specific lncRNA 
promoters57. Altogether, these discoveries have made the distinctions between enhancers and 
promoters less apparent  
 
1.1.3 Chromatin insulation 
It is evident that chromatin contacts are a fundamental requirement for the transcriptional 
functionality of the genome. Thus, to prevent aberrant transcriptional activation, the 
mammalian genome has evolved to form organisational structures, such as TADs and loops 
(Section 1.1.2), in order to locally constrain transcriptional activity in three dimensional space. 
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The formation and preservation of these structures requires a robust chromatin contact 
insulation system to prevent aberrant chromatin contacts and anomalous transcriptional 
activation within the human genome. By insulating the genome into discrete regions, 
chromatin insulators serve to segregate chromatic regions in the genome in a manner that is  
 
Figure 1-6: CTCF loops in transcription. Top panel: mammalian nucleus with chromosome territories (depicted 
in different colours) are made up of Topologically associating domains (TADs) which encompass several loops. 
Loop and TAD boarders are enriched with chromatin insulator protein CTCF (grey circles). Bottom panel: The 
CTCF protein binds to a non-palindromic 19 bp CTCF motif or binding site (CB, green bars), both forward and 
reverse. Both motifs are displayed here. CTCF binds to CBs as the chromatin is extruded by the “ring-like” 
multiprotein complex, cohesin (multi-coloured ring). Once two CTCF-bound CBs come into contact, the cohesin 
ring locks or “hand-cuffs: the CTCF-enriched chromatin contact between the CBs resulting in loop formation. The 
formation of loops and TADs by CTCF and cohesin allows for high frequency chromatin interactions to occur with 
the loop or TAD, such as those between enhancer (blue) and promoter (red) regions facilitating loop- or TAD- 
constricted transcriptional activity insulated from other regions of the chromatin, thus preventing aberrant chromatin 
contacts and subsequent transcriptional activation.  
 
permissive to their transcriptional and functional activities. The currently accepted model 
defining chromatin insulation is known as the loop extrusion model (Figure 1-6)13,58. In this 
model, the chromatin is extruded through cohesin, a ring-like complex, until two convergently 
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orientated and CTCF-enriched CTCF motifs block the cohesin-mediated extrusion. Following 
which, cohesin is thought to “hand-cuff” this contact resulting in the formation of a chromatin 




The dynamic three-dimensional organization of the chromatin is fundamental in regulating and 
mediating almost all cellular processes. The characterisation and visualization of higher -order 
chromatin organisation and the epigenome has undergone several technological advances in 
the last few decades. The techniques used for the detection and characterization of the  
epigenome are almost exclusively biochemical and are extensively discussed in Section 3.1.  
 
1.2.1 Visualizing the spatial organization of the genome using microscopy 
Traditionally, genomic conformation was largely based on microscopic techniques such as 
Fluorescence In-Situ Hybridization (FISH), which allows for the evaluation of spatial proximity 
between genetic loci at diffraction-limited resolution at a single-cell level. This technique can 
be used to target stretches of DNA or RNA in at single-molecule precision using DNA/RNA 
probes covalently linked to fluorescent dyes59,60. Indeed, this approach was the first to reveal 
the existence of chromatin territories. The co-localization of FISH probes within a fixed nucleus 
has been used to determine dynamic, and at times live, genomic loci proximities and 
transcriptomic activity in single-cells or whole organisms61,62. The integration of FISH and 
immunofluorescence (IF) techniques further revealed the clustering tendencies of active 
chromatin domains63. In the last decade, these techniques have advanced to encompass the 
automated visualization of the genome at high-throughput, -resolution, -precision in both fixed 
and live cells.  
  
1.2.2 Chromatin conformation capture techniques  
Chromatin looping interactions represent the basic organization structure of chromatin 
architecture. These chromatin contacts are typically identified using population-based 
“chromosome conformation capture” (3C) technologies64. 3C-derived technologies have 
revolutionized the field of chromatin organization, enabling the simultaneous detection of 
genome-wide chromatin contacts. Advances in 3C-derived technologies have led to several 
paradigm-shifting discoveries. Namely, the compartmentalization of chromosomes into a 
complex hierarchy of chromatin folding from kilobase range to multi-megabase sized 
compartments. Developed by Job Dekker and colleagues over ten years ago64, the 3C 
technique has evolved into several technologies classified by the types and ranges of 
chromatin contacts probed.  
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Briefly, during 3C,  a population of cells is chemically fixed with formaldehyde to allow for the 
formation of covalent bonding between chromatin segments. The cross-linked chromatin is 
then digested with a 4- or 6-bp restriction enzyme, which defines the resolution of the 
experiment, where 4-bp cutters yield higher-resolution libraries. The digested chromatin is 
then ligated to form proximity-based chromatin fragments which undergo reverse cross-linking 




1.3.1 The CTCF protein 
CTCF is a highly conserved multi-domain protein that binds chromatin in a sequence-specific 
manner through a tandem array of 11 Cys-His (C2H2) zinc finger domains (ZF)65. In classical 
C2H2 ZF proteins, two cysteine and two histidine amino acids on separate side chains are co-
ordinated by a single zinc ion66. Typically each ZF, in C2H2 ZF proteins, directly binds a 
double-stranded tri-nucleotide or “triplet” DNA element. The first high-resolution structure of  
CTCF ZFs in complex with chromatin, at the human/mouse H19/Igf2 locus, was elucidated by 
the Cheng lab where the ZFs 3-7 specifically bind to the major groove at the 15-bp core CTCF 
motif65 (Figure1-9).  In the same year, Yin and colleagues resolved the crystal structure of 
CTCF ZFs in complex with the CBs HS5-1a located on the PCDHα enhancer in HEK293T 
cells67. The CTCF ZFs 2, 8 and 9 are highly flexible structures that do not appear to make any 
base-specific contacts however recent evidence suggests these may play a role in stabilizing 
CTCF on to chromatin68. ZFs 1,10 and 11 do not appear to have a specific function in DNA 
recognition and thus, are thought to mediate co-factor65 and RNA69,70 binding.  
 
CTCF gene and CTCF protein sequences have been shown to be frequently mutated in an 
array of cancers. Specifically, the CTCF gene resides within the minimal deleted 16q22.1 
region in several cancers. In colorectal cancer (CRC) specifically, 11.24% of cases had  
 
Figure 1-7: CTCF ZF binding on to chromatin65. The zinc fingers 2-9 on the CTCF protein bind to its 15-bp core 
motif in an opposing orientation, with zinc fingers (ZFs) 3-7 specifically binding to the major grove of DNA, where 
the 15-bp core motif is located. The flexible ZFs 2,8, 9 do not form base-specific contacts with the chromatin, 
however the function to stabilize CTCF onto the DNA. 
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significant CTCF alterations with a mutational frequency of 4.87%  in 13 diploid CRC samples 
reported by TCGA71. These mutations span both the ZFs and the N-terminal regions. 
Specifically, the R339 mutation in ZF3 makes direct contact with C13 towards the 3’ end of 
the core CTCF motif implicating this mutation as a direct effector of CTCF binding onto 
chromatin71. Notably, mutations in other regions within the CTCF protein may, albeit indirectly, 
affect optimal CTCF binding.   
 
1.3.2 The CTCF motif 
The consensus CTCF motif sequence has been a subject of debate for the last thirty years. 
Identified in the chicken c-myc promoter 5’-flanking region, the CTCF motif was first described 
in 1990, using sequence-specific chromatography72. Lobanenkov et al. (1990) characterised 











Figure 1-8: Frequent mutations within the CTCF motif in gastric and colorectal cancers77–79. a. The total 
number of somatic substitutions at the CTCF binding site (CBS) and the 30 bp flanking region, in the 5’ and 3’ 
directions in 198 microsatellite-stable CRC Finnish matched tumor samples, as determined by whole genome 
sequencing mutational analysis by Mutect2 at 28 311 CBSs 78.   b. Distribution of the 453 CTCF motif-breaking 
mutations in 100 Chinese gastric cancer samples80 analysed by FunSeq279 c. Somatic substitution patterns at the 
CBS and the 5 bp flanking regions, in the 5’ and 3’ directions, at CBS mutational hotspots and all mutations, 
respectively. Data was obtained from whole genome sequencing of 40 matched gastric tumor samples from 






upstream from the transcriptional start site (TSS) of the chicken c-myc gene. This proposed 
motif spanned over 45 bp72. The deletion of the 110 bp region encompassing the CBS, which 
also included a Sp1 binding site and a poly(G)-binding protein motif, altered the transcriptional 
activity of the c-myc promoter72. In 1993, Klenova and colleagues identified 25 core 
nucleotides in both DNA strands that were required for CTCF binding at the same promoter73. 
Following the advent of ChIP-Seq technologies, Kim et al. identified a core consensus 20 bp 
motif sequence from over 75% of the 13 804 CBSs in human fibroblasts (IMR90), that 
displayed high conservation scores with other vertebrates74. In 2007, two ChIP-Seq studies 
identified 13 80474 and 20 26275 CBSs, respectively in different cell types namely HeLa, Jurkat 
and resting CD4+ T cells. The motif discovered by Barski et al in 2007,  MA0139.175 has been 
validated in multiple cell types, including 56 ENCODE cell lines76, and is currently accepted 
as the canonical CTCF motif predictive of CTCF binding (Figure 1-9). 
 
As initially described by Lobanenkov, the core CTCF motif (M1) requires additional flanking 
sequences for tight sequence binding. Over the years, an additional consensus upstream (U 
or M2) motif has been described. This M2 motif is an 9-10 bp motif, located 5-6 bp upstream 
from the core motif bound by ZF9-11, which is associated with ~15% of the CBSs  in the 
human genome81. Intriguingly, a 6 bp motif downstream from the canonical CBS has also been 
identified as a destabilizing CTCF binding motif 81.   
 
1.3.2.1 Mutations at the CTCF motif in cancer 
 
Although the CTCF motif has been known to play a fundamental role in directing CTCF binding 
to the chromatin, the first study to identify CBSs  as major somatic mutation hotspots in the 
non-coding genome was conducted in 201578. In this study, whole genome sequencing (WGS) 
analysis of 213 primary CRC samples, identified frequent point mutations at ChIP-Seq 
determined CBSs78. It is important to note, enrichment of CBS mutations in this study were  
described in the context of simultaneous cohesin binding, which are thought to represent only 
25% of the CBSs in the human genome. Along with other subsequent studies in gastric, 
hepatocellular, oesophageal and pancreatic cancers77–79, CBS mutations in CRC78 are highly 
associated with the AT>GC conversion at the adenosine nucleotide in the 9th position (A24) 
of the CTCF motif78 (Figure 1-7). This A24 base is located at the centre of the fully palindromic 
core of modules 2-3 of the CTCF motif. The A24 nucleotide is located within at tri-nucleotide 
bound by Q418 on ZF6, which has been shown to be essential for CTCF binding directionality 
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(Figure 1-7)67. CBS mutational  studies have identified somatic mutational hotspots in the 5’ 
flanking region, up to 5 bp, of the core CTCF motif in several cancers77–79 (Figure 1-8). These 
mutations are corelated with genomic instability, chromosomal architecture and transcriptomic 
aberrations found in cancer78. These results highlight the frequency and consequences of 
CBS mutations in cancer. However, whether these mutations are causative or merely 
correlated to oncogenesis is yet to be determined.   
 
1.3.3 DNA methylation  
It has become increasingly evident that the local genomic context may be as influential on 
transcriptomic activity as sequence variation. For the CTCF motif, the contextual variation is 
mediated by pre-existing DNA methylation and the presence of other chromatin binding 
proteins. Although, global DNA demethylation largely has no effect on global CTCF binding82, 
pre-existing DNA methylation at the canonical CBS antagonizes cell-type specific CTCF 
binding16,83.  DNA methylation of the canonical CBS sequence has been shown to regulate 
cell-type specific CTCF binding and its ability to bridge long-distance chromatin looping 
interactions between distal enhancers and their cognate promoters.  The C2 and C12 CpGs 
on the CTCF motif have been shown to have differential levels of methylation with the later 
exhibiting higher methylation84. Specifically, methylation at C2 of the CTCF motif has been 
shown to inhibit CTCF binding78  whereas the methylation of C12 enhances the binding of 
ZF4-765,83.  
The cancer-specific hypermethylation at the PDGFRA locus CBSs motifs at abrogates CTCF 
binding in IDH mutant gliomas16.  Several descriptions of CTCF binding abrogated by DNA 
methylation have been documented including at the MYC locus85. Taken together, this data 
suggests that CTCF binding, at a subset of cell-specific CBS motifs, is methylation-sensitive 
and alterations in their methylation status may play a role in oncogenesis.  It is important to 
note that the binding of CTCF onto pre-methylated CpG-poor regions can lead to the initiation 
and spreading of local demethylation spanning through and beyond the CTCF motif locus86,87. 
Thus far this phenomena has only been characterized at the PCDHα promoter where local 
demethylation is coupled to and driven by the transcription of the PCDHα aslncRNA87.    
 
1.3.4 Enhancer “docking-sites”   
Although CTCF does not typically occupy cis regulatory elements, when it does occupy these 
loci, CTCF facilitates enhancer-promoter contacts. An elegant study characterising CTCF 
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binding on the MYC locus by the Young lab established promoter-proximal and CTCF-
occupied CBSs as docking sites for multiple cell-specific enhancers88. Specifically, the 
constitutively CTCF-enriched CBS proximal to the MYC promoter, in various cancer cell lines, 
led to the docking of cancer- and cell-specific enhancers at this site. The formation of these 
enhancer-promoter contacts subsequently leads to the transcriptional activation of the MYC 
gene in a cancer-specific manner. Each of the forementioned contacts were lost upon the 
abrogation of CTCF occupancy by CRISPR-mediated deletion and/or methylation of the 
promoter-proximal CBS. Similar results were also observed at the promoters of TGIF1, 
VEGFA, RUNX1 and PIM188. This emerging research implicates CTCF in the regulation of 
enhancer-promoter contacts.  
 
1.3.5 RNA interactions  
Recent studies have associated RNA expression and binding to the CTCF protein as a 
cognate mechanism for establishing a  chromatin loops, TADs, promoter-enhancer contacts 
and intra-TAD transcriptional activity (Section 1.6.4.2).  CTCF has been shown to bind 
lncRNAs FIRRE89 and HOTTIP90 to promote locus specific CTCF binding while CTCF binding 
to Jpx has been shown occlude CTCF from chromatin91. The TP53 antisense lncRNA, Wrap53 
was also shown to bind directly to CTCF70, implicating the CTCF-lncRNA binding event in the 
activation of TP53 transcription92. CTCF-RNA interactions affecting CTCF binding onto 
chromatin have been demonstrated by alterations in the CTCF-RNA binding domain located 
at the C-terminus of the CTCF protein69,70. Together these findings suggest CTCF-RNA and/or 
CTCF-lncRNA may play a role in regulating CTCF docking onto chromatin .  
 
Earlier this year, the Maniatis lab demonstrated the requirement of antisense lncRNA 
transcription in the facilitation of CTCF binding at the PCDHα promoter by specifically 
demethylating said promoter CBSs87. This lncRNA-mediated mechanism then allows the 
HS51 enhancer to bind demethylated protocadherin promoters leading to their transcriptional 
activation87. Furthermore, John Rinn and colleagues demonstrated that the deletion of the 
Firre lncRNA locus, and not the inter-TAD CTCF boundary site, led to the disruption of the 
DXZ4 super-loop and its internal interactions in mouse embryonic fibroblasts (MEFs)89. 
Together these studies present a novel CTCF binding mechanism that may be reliant lncRNA 
transcription, and/or CTCF-RNA interactions to regulate the organisational structure of 
chromatin and its transcriptional activity. It is important to note that the specificity of CTCF-




1.6.5 Loss of inter-TAD CTCF binding alters genome topology  
The functional role of inter-TAD CTCF binding on genome topology and transcriptional 
activation has been a subject of debate with several studies demonstrating somewhat 
disparate observations. For instance, acute depletion of CTCF leads to a global loss of 
chromatin loops and TAD structures affecting cell survival with only marginal effects on 
chromatin contacts and transcription93,94. Similar results were obtained upon acute depletion 
of cohesin in HCT116 cells95. Together these studies suggest that alternate mechanisms may 
be responsible for the establishment and maintenance of  transcriptional compartments within 
TAD structures.   
 
 
Figure 1-9: Representative Hi-C maps on CTCF motif disruptions affecting CTCF binding including 
mutations, deletions and/or increased methylation. An example of a chromatin contact map encompassing two 
TADs, one of which contains two sub-TADs. (Top panel)  Inter-TAD CTCF motif disruptions typically lead to the 
reconfiguration of TAD structures, which results in ectopic chromatin contacts (Bottom left panel). Intra-TAD 
CTCF motif disruptions maintain TAD structure but lead to ectopic intra-TAD chromatin contacts (Bottom right 
panel). Wild type contacts displayed in blue and ectopic contacts in red where color intensity is indicative contact 




In some studies, deletions or alterations of a single CBS, or a minimal region surrounding a 
CTCF motif, is sufficient to alter TAD boundaries and rewire promoter-enhancer interactions. 
A classical study validating this phenomena was conducted by Lupiáñez and colleagues, 
where CRISPR-mediated structural variations at Epha4 inter-TAD CBS led to TAD fusions 
and ectopic contacts between the Epha4 enhancer, Pax3 and Ihh genes. The loss of these 
contacts resulted in aberrant expression of these genes as well as phenotypic abnormalities, 
in mouse embryos15. Recently however, a similar study in which serial deletions of inter- and 
intra-TAD CBSs at the Sox9 and Kcnj2 TADs were formed in the same cell type, revealed that 
alterations these inter-TAD CBSs alone, did not modify TAD configurations and or 
transcriptional activity96. These apparent discrepancies suggest a redundant system that 
requires both inter- and intra-TAD CBSs and as well as other additional mechanisms, including 
cohesin binding and transcriptional compartments, to form internal enhancer-promoter 
contacts within TADs. Other studies have reported local TAD boundary disruptions occurring 
only after the deletion of large genomic regions spanning up to 400 kb around discrete inter-
TAD CBSs7,96.  This introduces another conundrum and further re-enforces the lack of 
exclusivity of CTCF binding at inter-TAD binding sites in mediating chromatin organisation. 
 
1.3.6 Loss of intra-TAD CTCF binding alters promoter-enhancer contacts  
Intra-TAD CBSs have been shown to stabilize promoter-enhancer interactions resulting in 
robust promoter activity and minimal cell-to-cell transcriptional variation97. These CTCF-
mediated enhancer-promoter interactions, as demonstrated in mouse lymphomas and 
embryonic stem cells, may be further stabilized by a positive feedback loop through the 
transcripts arising from participating promoters97,98. Intra-TAD CBSs have been shown to 
function as enhancer “docking sites” in several cancer cell lines leading to cancer-specific 
transcriptional activity88. This was elegantly demonstrated at the MYC oncogene locus, where 
the CBS located 2 kb upstream of the MYC promoter promotes interactions with cancer-




Figure 1-10: Promoter-associated CTCF biding sites function as tissue specific “enhancer” docking sites 
whose functioning is regulated by CTCF binding. Abrogated CTCF binding, by methylation (dCas9/DNMT3A-
3L)  and/or sequence mutation  (CRISPR/Cas9) at CTCF enhancer “docking sites”  leads to loss of promoter-
enhancer contacts leading to a loss of transcription at proto-oncogene promoter region..  
 
The binding of CTCF at these promoter-associated (PA) intra-TAD CBSs allowed for the 
“docking” of the MYC gene onto cognate cancer-specific enhancer regions resulting in 
increased MYC promoter activity. Disruption of these PA-intra-TAD CTCF “docking sites” by 
DNA methylation abrogated enhancer-promoter contacts as well as the transcription of the 
MYC oncogene88.  Notably, these PA-intra-TAD CBSs are hypomethylated in diverse cancer 
cell lines, including HCT116,  facilitating CTCF binding and transcriptional activity at the MYC, 




Globally, fatalities from communicable diseases have decreased significantly however the 
mortality rates for cancer have increased by over 40% in the past 40 years. In fact, cancer has 
emerged as the greatest health epidemic of our time. Cancer mortality is currently on the rise 
and expected to increase by 70% globally in the next ten years99. Breast, prostate and 
colorectal cancer (CRC) are the most prevalent cancers throughout the developed and 
developing world100. CRC predominantly accounts for approximately 10% of cancer-related 
mortalities in the developed world101. CRC is also the third most commonly diagnosed 
malignancy in men and the second in women, with over 1.8 million new cases reported in 
2018102 and the fourth most leading cause of death globally. In South Africa, where CRC is 
the fourth most common and sixth most lethal cancer103, the cumulative risk of CRC incidence 
rate is currently at 14.4% (Figure 1-13)104.  
 
 
Figure 1-11: Estimated age-standardized incidence rates (World) in 2018, colorectum, both sexes, all 
ages104 
 
Notably, up to 30% of CRC patients have a family history of hereditary colorectal syndromes 
such as hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) and familial 
adenomatous polyposis (FAP)105. Most CRC tumors are found in the rectum or sigmoid colon. 
In the last 50 years, some studies have reported a distal-to-proximal shift (left-to-right shift) in 
the anatomical distribution of CRC tumors making proximal tumors increasingly common106.  
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Microsatelite instability (MSI) and CGI methylator phenotype (CIMP) tumors are more frequent 
in proximal cancers while chromosomal instability (CIN) cancers are frequently distal107.   
 
 
Human cancers are fundamentally heterogeneous with distinct subtypes associated with 
differences in genetic, molecular, cellular, pathological and clinical proclivities. Coupled to 
these complexities, are the histopathological and genetic variations observed between tumors 
arising from the same organ (inter-tumoral) and within individual tumors (intra-tumoral), both  
across populations and within the same individual. Multiple attempts have been made to 
investigate, classify and catalogue the diversity observed in CRC tumors for improved 
diagnosis and therapy. Like most solid tumors, CRC is a heterogeneous disease in which 
different subtypes can be distinguished by their clinical and/or molecular features. The majority 
of CRCs are sporadic (70-80%) while approximately 20-30% have a hereditary component 
due to rare high-risk susceptibility syndromes such as including Lynch Syndrome (LS) (3-4%) 
and familial adenomatous polyposis (FAP) (~1%)108. Notably, a small subset of CRC cases 
can arise as a consequence of inflammatory bowel diseases (IBD)109. 
 
Sporadic CRCs develop from one or a combination of the following molecular mechanisms: 
chromosomal instability (CIN), CpG island methylator phenotype (CIMP) and microsatellite 
instability (MSI)102 (Figure 1-14). Recently, the International CRC Subtyping Consortium 
(CRCSC) and The Cancer Genome Atlas (TCGA)  introduced a four subtype consensus 
molecular classification system for CRC tumors (Figure 1-14)110. Using data from 4151 
patients, six CRC subtyping algorithms, integrated datasets and multiple analytical 
approaches, the consortium described the following consensus molecular subtypes (CMS’):  
1. CMS1 MS subtype: 
These tumors are frequently associated with MSI, CIMP and the BRAFV600E mutation. 
Histopathologically, these tumors display a diffuse immune infiltrate and activated JAK-
STAT pathways.  
2. CMS2 canonical subtype: 
Classified by an epithelial gene-expression signature in the majority of CRC tumors, 
this subtype it is thought to follow a canonical path of CRC progression (Section 1.4) 





Figure 1-12: Proposed taxonomy of colorectal cancer based on the biological differences observed in 
gene-expression molecular subtypes. CIMP; CpG island methylator phenotype. MSI; microsatellite instability. 
SCNA: Somatic copy number alterations110. 
3. CMS3 metabolic subtype:  
Based on transcriptomic data, these tumors are characterised by KRAS mutations and 
are associated with deregulated metabolic processes. Like CMS2, CMS3 tumors  also 
display a specific epithelial gene-expression profile with activated integrin-β3, TGF- β 




4. CMS4 mesenchymal:  
The upregulated genes in these tumors are integral to signal pathways including: 
epithelial-mesenchymal transition, angiogenesis, cellular proliferation and extra-cellular 
matrix remodelling.   
 
Importantly, over 13% of the CRC tumors studied represent either mixed or intermediary 
subtypes, and as such could not be classified using this system. This suggests more subtypes 
of CRC are yet to be described. Since the unveiling of the four CRC subtypes, the Catalogue 
of Somatic Mutations in Cancer (COSMIC) consortium has curated the somatic mutation 
profiles associated with 7 815 whole exome sequencing (WES) datasets across 26 cancers 
including CRC. Over 500 colon and rectum adenocarcinoma (COAD and READ) datasets 




Cancer is caused by the accumulation of multiple genetic mutations. Typically beginning with 
a single or combination of oncogene activation which commence the “drive” to cancer. A major 
hurdle in the identification of these essential “cancer driver” mutations is that most CRC tumors 
have acquired thousands of MSI or CIN harbouring mutations. In the past, CRC 
characterization studies have largely focussed on somatic or acquired somatic predictive and 
prognostic mutational markers in the coding genome. First described by Fearon and 
Vogelstein over thirty years ago, CRC somatic markers follow the adenoma-carcinoma 
sequence (Figure 1-13)112.  
 
 
Figure 1-13: Adenoma-carcinoma sequence in intestinal epithelium101. The top panel represents the sequence 
in classical CIN and MSI cancer. Beginning with mutations in the APC gene, followed by mutations in the KRAS, 
PTEN/PIK3CA and TGF-β genes in CIMP cancers. Sporadic MSI cancers also begin with mutations in the APC 
gene and are followed by NRAS, SMAD4 and TP53 mutations.   
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The adenoma-carcinoma sequence refers to the progressive and cumulative acquisition of 
genetic abnormalities that lead to CIN CRC tumors112. These include a combination of 
oncogene activation (e.g. Kristen Rat Sacroma (KRAS), Phosphatidylinositol 3-Kinase 
catalytic p110-alpha subunit  (PIK3CA)) and tumor suppressor gene inactivation (e.g. 
Adenomatous Polyposis Coli (APC), Mothers against decapentaplegic homolog 4 (SMAD4) 
and Tumor Protein 53 (TP53)). The mutational aberrations of these genes are now well 
characterized, and have been shown to involve the dysregulation of five core signalling 
pathways; WNT/, Ras/mitogen-activated protein kinase (MAPK), tumor protein 53 (p53), 
phosphoinositide 3-kinase (PI3K), and transforming growth factor beta (TGF-β)/SMAD4 
(Figure 1-13).  
 
1.4.1. CRC driver genes and pathways 
A prevailing paradigm is that CRCs develop by the progressive accumulation of key genetic 
and epigenetic alterations in colonic-crypt resident cells, that lead to the transformation of 
normal colonic epithelium to colon adenocarcinomas. CIN sporadic CRCs are associated with 
gross changes in chromosome number and structure including translocations, gains or losses 
of chromosomal segments and loss of heterozygosity (LOH). Each of these results in gene 
copy number variations (CNVs) that affect the expression of genes that regulate cell 
proliferation, cell cycle check points as well as tumor-associated gene expression. Classical 
CIN CRC oncogenesis (Figure 1-13) is characterized by the sequential accumulation of 
mutations in the “driver genes”; APC113, KRAS and TP53112, which are associated with over 
70% of sporadic CRCs .  Mutational abnormalities in other loci including; PIK3CA, Deleted in 
Colorectal Cancer (DCC), SMAD2, SMAD4 and TCFβ have also been reported in CRC, 
however these mutations only appear to function in the context of pre-existing APC, KRAS 
and/or TP53 mutations (reviewed in 114). 
1.4.1.1. WNT pathway dysregulation in CRC: APC mutations 
Arguably, the earliest event in the adenoma-carcinoma sequence is the mutational inactivation 
of the APC gene, which occurs in over 80% of CRC CSM2 adenomas. The most common 
mutations in the APC gene initiate the formation of benign polyps through the hyperactivation 
of WNT signalling115. APC is a tumor-suppressor and potent inhibitor of the WNT pathway. 
APC is a component of the Axin-APC degradosome complex that earmarks β-catenin, a WNT 
effector, for degradation through phosphorylation. DNA hypermethylation at the APC promoter 
has also been implicated with APC inactivation in CRC116. The inactivation of APC observed 
in CRC, leads to excess cytoplasmic β-catenin followed by its translocation into the 
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nucleus117,118. Once in the nucleus, β-catenin forms a transcriptional activator complex with 
TCF4, leading to the transcriptional activation of several genes including the MYC proto-
oncogene119. This leads to a dysregulation of cellular proliferation and differentiation leading 
to the development of dysplastic crypts (Figure 1-13).  
 
1.4.1.2. EGR pathway dysregulation in CRC: KRAS mutations 
Proceeding APC mutations in crypt-resident epithelial cells are mutations in the KRAS gene. 
Mutations in KRAS appear to initiate aberrant crypt foci, an early event in adenoma 
formation120 (Figure 1-13). KRAS mutations have been found in approximately 50% of CRC 
cases, the majority of which are associated with the CSM3 molecular signature (Figure 1-12). 
KRAS is a proto-oncogene that encodes a small membrane-bound GTPase downstream of 
the EGFR signalling pathway that activates EGFR ligands including EGF and TGFα121 
Mutations in KRAS, abrogate its GTPase activity, which leads to the constitutive activation of 
the EGF pathway resulting in  incessant cellular proliferation and tumor growth.  Activated or 
GTP-bound KRAS also inhibits apoptosis by activating P13K, which in turn activates AKT, a 
potent pro-survival kinase that inhibits apoptosis through several mechanisms including 
inactivating the pro-apoptotic BCL2 proteins122. This results in an internal microenvironment 
conducive for metastasis in the colonic epithelium123. Thus, KRAS has been established as a 
potent driver of CRC invasion and metastasis. Unfortunately, KRAS is still considered an 
undruggable target.  
 
1.4.1.3. TP53 pathway dysregulation in CRC: TP53 mutations 
The transition from adenoma to malignant carcinoma is usually associated with mutation and 
subsequent LOH of TP53 in CRC tumors. TP53 is a tumor suppressor gene that has been 
termed as the “guardian of the genome” as it encodes a critical growth suppressor protein that 
transcriptionally regulates hundreds of genes involved in fundamental cellular processes 
including DNA repair, senescence, cell cycle arrest, metabolism and apoptosis in response to 
a number of environmental cues including DNA damage. The mutational dysfunction of TP53 
is considered as a universal hallmark of cancer. In CRC specifically, TP53 LOH has been 
reported in 4%–26% of adenomas, 50% of adenomas with invasive foci, and in 50%–75% of 
CRC tumors124. Notably, TP53 mutational frequencies are higher in distal colon and rectal 
tumors as compared to proximal rightward tumors125. Mutational dysfunctionalities in TP53 
result in the loss of its ability to block cellular proliferation, particularly in the context of DNA 
damage. Thus, loss of TP53 leads to the propagation of damaged DNA into daughter cells 
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further contributing to mutational selection within the colonic epithelium and promoting the 
transition from adenomas to carcinomas (Figure 1-15)124.  
 
1.4.1.3. P13K/AKT pathway dysregulation in CRC: PIK3CA mutations 
Occurring late in the adenoma-carcinoma sequence, PIK3CA mutational dysregulation occurs 
in approximately 25% of CRC tumors. PIK3CA mutations have been frequently associated 
with poor prognosis in the context of KRAS mutational activation126,127. The PIK3CA gene 
encodes for the catalytic p110-alpha subunit of Phosphatidylinositol 3-Kinase (PI3K) alpha, 
that binds the PI3K regulatory subunits which function in a variety of cellular processes, 
including cellular proliferation and migration. The PI3K protein family, including PIK3CA, are 
responsible for the phosphorylation of phosphatidylinositol lipids upon activation by several 
growth factors including EGF and VEGF. In normal cells, the tumor suppressor PTEN inhibits 
the PI3K signalling pathway preventing cellular proliferation. However, in numerous tumors 
where PTEN and PIK3CA are typically mutationally inactivated, aberrant PI3K responsiveness 
to EGFR activation results  in  increased cellular growth and survival. Indeed, EGFR-inhibitors 
have been shown to have promising therapeutic potential with PI3K inhibition reversing EGFR 
inhibitor resistance in cancer patients128. Thus, together PTEN/PIK3CA mutational 
dysregulation plays a significant role facilitating CRC metastasis (Figure 1-13) highlighting it’s 
therapeutic capability.  
 
1.4.2. CRC driver lncRNAs 
Most cancer-related mutations occur in regions of the genome outside of genes. Thus, it is 
unsurprising that oncogenic lncRNA expression, has been implicated in the progression of 
CRC oncogenesis, similar to the “driver genes” reported. These lncRNAs are summarized in 
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Globally CRC tumors are hypomethylated compared to normal colonic tissue132 primarily 
within repetitive elements such as LINE-1 and ALU elements, which contributes to CRC 
initiation and increasing genomic instability133. However, within this global hypomethylated 
state, a subset of gene promoters are hypermethylated in CRC, particularly in CIMP tumors. 
Ordinarily, hypermethylation corresponds with reduced promoter activity due to the lack of 
transcription factor and subsequently Pol II accessibility at hypermethylated promoters, 
however hypermethylation can also lead to increased transcriptional activity. In CRC fewer 
than 10% of methylated genes been shown to have a corresponding decrease in 
transcriptional activity134.  
 
Alterations in the methylation status of the core “cancer driver” genes and/or their respective 
pathways have been reported. The presence and functioning of hypermethylation on the APC 
promoter is yet to be established. Although, one study has suggested that the APC promoter 
may be hypermethylated in approximately 20% of CRC tumors135.  In addition, Several 
components and targets of the WNT signalling pathway, including SFRP1 and LGR5,  have 
been reported to be hypermethylated (reviewed in136). To date, hypermethylation at the TP53 
promoter in CRC tumors has not been studied, however the TP53 target gene IGFBP7 has 
been reported as methylated in CIMP+ CRC tumors, which leads to the inactivation of the 
TP53 pathway137. Similarly, no effectors or targets of the KRAS pathway have been found to 
be methylated. Methylation at the PIK3CA promoter has been linked to poor prognosis in 
CRC138, although the functional mechanism has not yet been established. The P13K/AKT 
negative regulator, PTEN however has been shown to be hypermethylated corresponding to 
a loss in transcriptional activity in 2% and 20% of MSS and MSI CRC tumors, respectively139.  
In the TGF-β pathway, promoter hypermethylation and downregulation has only been reported 
in TGF-β regulator TSP1140.  
 
Together these studies suggest DNA methylation is a powerful epigenetic regulator of 
transcriptional activity. However, the mechanisms of how a specific promoter will respond to 
DNA methylation i.e. transcriptional repression or activation are currently unclear. DNA 
methylation at specific gene promoters, particularly at oncogenes,  has been repeatedly 
demonstrated as a powerful prognostic marker. This highlights the need to extensively 
characterise and distinguish driver and passenger methylation events in CRC tumorigenesis.  
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 : Study aims and objectives  
Identify and characterise promoter-associated CTCF binding sites with lower CTCF 
enrichment in CRC  
 
Objectives 
1. Develop a ChIP-Seq analysis pipeline, using open-source analysis tools, to identify 
differential ChIP-Seq enrichment sites.   
2. Identifying promoter-associated genomic loci with lower CTCF enrichment (PA-LCe) 
using ENCODE ChIP-Seq datasets.  
3. Identification of canonical CTCF motifs (MA0139.1) at PA-LCe regions in CRC. 




 Designing a promoter-associated lower CTCF 
enrichment (PA-LCe) site discovery pipeline using ChIP-
Seq data 
It has become increasingly evident that local genomic context influences transcription as 
strongly as sequence variation. The context of the genomic landscape is mediated by several 
extragenic factors that bind chromatin and regulate its functional activity. Intragenic factors 
mediating transcriptional regulation include enhancer regions while extragenic factors can be 
histone modifications, transcriptional machinery, lncRNAs as well as  chromatin-contact 
insulators such as CTCF. Together these factors mediate transcription primarily through 
mediating chromatin contacts or “chromatin kisses”. The transcriptional status of the 
interacting sequences can have significant effects on all aspects of cellular functioning, and 
are therefore tightly controlled. Promiscuous and aberrant chromatin interactions can lead to 
a host of dysregulated transcriptional activities that can accumulate into systemic phenotypes 
such as cancer. Thus, detecting and regulating these cancer-driving interactions will advance 
our ability to diagnose and target these interactions with genomic precision. 
 
Like all physical interactions, a fundamental requirement of chromatin contacts is proximity 
along the linear genome or through 3D contacts. In mammalian genomes, proximity is 
regulated by genome segregating proteins and complexes like CTCF, whose primary role is 
to bind to the chromatin and establish highly specific chromatin interactions that result in the 
formation of dynamic chromatin loops. Chromatin loops are formed when two convergently 
oriented and CTCF-occupied motifs interact. This interaction is then “hand-cuffed” by multi-
protein complex, cohesin resulting in the formation of a chromatin loop.  This loop structure 
serves to constrain the physical space that the internal loop, or intra-domain, sequences 
occupy. Chromatin loops also serve to increase the three-dimensional distance between 
genomic sequences that are located in different loops preventing inter-domain interactions.  
Chromatin loops can exist within other loops to forming structures known as TADs, whose 
boundaries are strongly demarcated by CTCF-bound motifs which also serve to constrain 




CTCF binding sites (CBSs) at TAD boundaries, also known as inter-TAD CBSs, have been 
extensively studied. Early studies suggested that disruptions of inter-TAD CBSs, through the 
dysregulation of CTCF motif sequences and/or DNA methylation led to the reconfiguration of 
TAD structures resulting in the formation of ectopic chromatin contacts and alterations in  
transcriptional activity. However, recent experiments have suggested that the primary effect 
of disrupting inter-TAD CBSs is the alteration of the chromatin contact landscape. Recently, 
the focus has shifted to characterizing the role of intra-TAD CBSs in the regulation of contact-
dependent transcription. Intriguingly, the disruption of intra-TAD CBSs has been demonstrated 
to result in the destabilization of promoter-enhancer interactions leading to fluctuations in 
promoter activity. Intra-TAD CBSs proximal to promoters have emerged as potent 
transcriptional regulators functioning as “docking sites” (Section 1.3.4) for enhancers in a cell- 
and context-specific manner. It has been shown in some cancers that oncogenes hijack 
enhancers using this CTCF-mediated docking mechanism resulting in cancer-specific 
promoter-enhancer contacts and oncogenic transcription88(Section 1.3.4). These promoter-
proximal intra-TAD CBSs can be abrogated by genetic and epigenetic editing and thus present 
intra-TAD CBSs as oncogenic targets. Decreasing CTCF enrichment at these oncogenic 
promoter-associated intra-CBSs results in the abrogation of cancer-specific contacts and 
transcriptional activity. Thus, promoter-associated lower CTCF-enrichment (PA-LCe) CBSs 
could function as diagnostic and therapeutic candidates in cancer.  
 
With CTCF binding playing such a fundamental role in the regulation of chromatin structure 
and transcriptional activity, we sought to identify differentially enriched promoter-associated 
CBSs that may play a role in promoting CRC oncogenesis. In this study we define protomer-
associated lower CTCF-enrichment CBSs as canonical CTCF motifs within <1kb away from 
an annotated protomer-TSS with significantly reduced CTCF enrichment in the cancer cell line 
datasets as compared to the wild type/primary dataset. Only two concrete criterion are 
required for PA-LCe genomic regions. 
1. Lower CTCF enrichment in the cancer dataset as compared to primary/wild-type 
cells.  
2. The PA-LCe genomic region must be <1kb away from the closest annotated TSS in 





To this end, we  developed a PA-LCe CBS discovery pipeline to analyze publicly available 
CTCF ChIP-Seq datasets in colonic tissues and CRC cancer cell lines. Several challenges 
with regard to the determination of cancer-specific CBSs exist. The most significant being the 
availability of primary and cancer patient samples that can be used for analysis as well as the 
cost of sequencing. However, this is partially mitigated by the increasing repertoire of 
catalogued and publicly available ChIP-Seq datasets such as those within the ENCODE 
database. Thus, in this study we employed the use of ENCODE CTCF ChIP-Seq datasets to 
identify differentially enriched promoter-proximal CBSs between normal colonic tissues and 




3.1.1 ChIP-Seq Experiment 
Described over three decades ago, chromatin immunoprecipitation (ChIP) has been 
repeatedly used to directly map protein-DNA interactions in vivo141. Briefly, in ChIP 
experiments, an antibody targeting a specific DBP is used to enrich for DNA fragments bound 
to said DBP (Figure 3-1). These enriched sites are then identified and quantified (Figure 3-
1). ChIP, however, has several limitations most notably the resolution and accuracy in 
determine CBSs loci, particularly within gigabase-sized vertebrate genomes. Almost twenty 
years later, these limitations were circumvented by the Wold lab, who performed ChIP with 
high-throughput DNA-sequencing (ChIP-Seq)142. As compared to ChIP,  ChIP-enriched DNA 
fragments in ChIP-Seq are directly sequenced providing higher resolution, low signal-to-noise 
ratios, greater coverage and fewer artefacts at relatively low cost (Figure 3-1). Recently, ChIP-
Seq extended techniques such ChIP-exo143 and ChIP-nexus144 have been developed to detect 
DNA-protein binding sites at base-pair resolution, however these techniques have as of yet 
been applied to a limited number of contexts.  
 
To date, thousands of ChIP-Seq experiments in various contexts have been conducted thus 
creating a need for recommended experimental standards and guidelines to ensure 
reproducibility and comparability. The most widely accepted guidelines have been developed 
by the ENCODE Consortium (Box 3.1). In an ideal ChIP-Seq experiment (Figure 3.1, Box 
2.1), the DNA fragments physically associated with a specific protein are enriched through 
antibody-based binding. Physical DNA-protein interactions are cross-linked in vivo using 
formaldehyde. The cross-linked chromatin is then sheared by sonication into 200-600 bp 
fragments. Protein bound and sheared DNA fragments then are enriched by 
immunoprecipitation, and cross-linking is reversed using high temperature exposure allowing 
for the release of target DNA,  which is then used for the preparation of a sequencing library. 
The sequencing library is then prepared by a combination of end-repair, phosphorylation and 
polyA-tailing, index adapter ligation, denaturation and amplification dependant on the 





Figure 3-1: Schematic of general ChIP-Seq experiment145. a. Chromatin is crosslinked and sheared b. 
Enrichment of DNA binding protein by immunoprecipitation. c. Addition of adapters for end repair and 
phosphorylation. d. bridge PCR on Illumina ChIP and sequencing. 
Box 3-1: ENCODE ChIP-Seq Guidelines 
I) Standard Measurements for Common ENCODE Cell 
Types 
To ensure consistency in cell cultures, ENCODE has 
designated common cell types to be used.  These include 
specific culturing instructions, including; cell density, 
passage number, cell cycle, gene expression, 
mycoplasma testing and  cell freezing standards to be used 
and recorded for data submission.   
II) ENCODE Standards for ChIP-seq Experiments 
IIa. Antibody Characterization and Epitope Tagging 
To ensure reproducibility of ChIP-Seq data,  a set of 
standards for primary and secondary antibody 
characterization have been developed. Primary 
characterization assays include blots, IP Mass 
spectrometry. Biochemical and bioinformatic secondary 
characterization assays including 1. RNA interference 
(RNAi) against target protein, 2. Immunoblotting of epitope-
tagged transcription factor, 3. Motif analysis at high quality 
peaks with an Irreproducible discovery rate (IDR) less than 
0.01.  
IIb. ChIP-seq Data Production Standards 
Sequencing Depth 
ChIP-Seq data must be Illumina sequenced with 10-30 
million raw reads. 
Signal-to-noise ratio 
ENCODE endorses a non-redundant fraction > 0.8 for a 
library of 10 million raw reads. 
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ChIP-Seq analysis standards have also been developed by the ENCODE Consortium (Box 
3-1) and typically involve the mapping of sequenced reads to a genome assembly, index 
generation, calling of peaks from mapped reads and the discovery of motifs within called peaks 
(Figure 3-2). Analysis pipelines have evolved from only extracting protein bound regions to 
differential binding analysis specifically for phenotypically comparable conditions i.e. healthy, 
diseased and treated conditions. A typical analysis pipeline will follow the ChIP-Seq analysis 
steps shown in Figure 3.2. However, ChIP-Seq analysis workflows and pipelines vary widely 
in different datasets. To circumvent this variability and the data quality issues that may arise, 
ENCODE standardized guidelines, practises, quality metrics and tools have been developed 
to standardize the analysis of replicated and un-replicated ChIP-Seq data ( Box 3.1). 
 
3.1.2.1 ChIP-Seq Datasets  
Despite, the availability of standardized methods, ChIP-Seq analysis is still largely 
customizable which tends to lead to technical biases. Thus, the choice of downstream ChIP-
Seq analysis strategies are dependent on several dataset and sequencing-related factors 
including, but not limited to: 
 
(1) Sequencing coverage/depth;  
Sequencing coverage/depth refers to the average number of unique reads that align to known 
genome reference bases i.e. number reads X read length/target size.  Typically, for a point-
source DNA-binding proteins or factors (DBPs), the number of positive ChIP-Seq sites 
detected increases with the number of sequenced reads. The increased number of reads 
provides higher statistical power which allows for the ability to detect lower-affinity sites with 
greater confidence. On the other hand, the number of peaks detected in point-source DBP 
ChIP-Seq data tends to saturate at approximately 30 million mapped reads, thus current 
ENCODE standards require that each replicate for point-source DBPs have a minimum of 10 
million uniquely mapped reads.  
 
(2) Read length and type,  
Typically longer single-end (SE) reads have higher genome alignment rates as compared to 
short SE reads, largely due to their increased sequence uniqueness146. However, for paired-
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end (PE) reads, median read lengths appear to improve alignment rates. Notably, PE reads 
tend to have higher genome coverage rates, particularly over repeat regions, as compared to 
SE reads of the same length. 
 
(3) Library complexity; 
Defined as the fraction of nonredundant DNA fragments in the library ( ), library 
complexity can have significant impact on site discovery and reproducibility in a sequencing 
experiment146. Although, increasing sequencing depth can increase the number of positive 
sites detected, at some point complexity can be exhausted with the same PCR-amplified 
fragments repeatedly sequenced to reach greater sequencing depths. This effect can be 
measured using the PCR bottleneck co-efficient (PBC) which determines whether the 
distribution of read counts per loci is skewed towards a single read per location. The PBC is 
defined as the fraction of genomic locations with exactly one unique read versus those covered 
by at least one unique read147. Using this metric, datasets can be classified as having; severe 
bottlenecking (0≤PBC≥0.5), moderate bottlenecking (0.5≤PBC≥0.8), mild 
bottlenecking(0≤PBC≥0.5), and no bottlenecking (0≤PBC≥0.5). Samples with severe 
bottlenecking (0≤PBC≥0.5) values indicate a technical problem with the datasets, such as 
PCR bias.  
 
ENCODE uses the Non-Redundant Fraction mapped reads (NRF) scores,   ,  
as a library complexity quality control metric for point source DBPs. Simply put, the NRF is 
defined as the ratio between the number of distinct uniquely mapped reads and the total 
number of reads. It is important to note that increasing sequencing depths results in lower 
NRF scores.  
 
 (4) The availability of a control or input sample.  
The non-uniform DNA breakage during sonication in ChIP-Seq experiments, caused by the 
overrepresentation of open regions of chromatin underpins the need for a control or input 
sample for ChIP-Seq analysis. Furthermore, aneuploid cell lines with large genomic 
duplications can influence called peak sizes and rankings. The use of control or input samples. 
therefore substantially alleviates these biases. Control samples typically involve the use of a 
non-nuclear antigen binding control antibody such as Immunoglobulin (IgG) whereas input 
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(5) The availability of replicates 
As with most experimental approaches, the use of at least two replicates ensures greater 
reproducibility and data confidence. Although ENCODE recommends at least two biological 
replicates for ChIP-Sequencing in cases where the availability of experimental material, such 
as patient biopsy samples, can be exempted however in such cases the data has limited value 
and data confidence.  
 
(6) The quality of the antibody used 
Arguably, the most influential technical feature on the quality of the ChIP-Seq data produced 
is the antibody to capture the chromatin during the first step the ChIP-Seq experiment. The 
affinity, specificity and cross-reactivity of the antibody used in a ChIP-Seq experiment can 
introduce significant technical bias thus affecting sequencing depth. The same experiment 
using the different antibodies targeted to the same protein, or even using the same antibody 
in different samples can produce completely different peak distributions. As a result, the 
ENCODE Consortium has implemented multiple TF antibody characterization methods and 
thresholds in an attempt to mitigate the these technical bias. However, it is important to note 
that despite each of these experimental validations/checkpoints, biases caused by the 





3.1.2.2 ChIP-Seq Analysis tools  
3.1.2.2.1 Read quality metrics 
Prior to mapping sequenced reads to the reference genome of choice, reads are typically 
filtered by applying a several quality cut offs. A report detailing the raw read quality, 
sequencing errors or biases can be obtained by running quality control algorithms such as 
FastQC148. FastQC assess GC content, the over-abundance of adaptors and over-
represented sequences which may indicate PCR duplication rates. Phred quality scores, 
denoted as MAPQ, can also be used to describe base call confidences in each sequence tag. 
These scores infer error probabilities and can be used to inform the filtration of low-quality 
reads and read trimming. A  base with a MAPQ of 50 for example, means that there is only a 
1 in 100 000 chance that base has been called incorrectly. A widely accepted Phred base 
score is typically ≥30.   
 
3.1.2.2.1  Read mapping  
Arguably, the most crucial early stage of sequencing data analysis is DNA read 
alignment/mapping. Briefly, read mapping refers to the process of aligning or mapping 
sequenced reads (FASTA or FASTQ) onto a reference genome in order to determine the 
genomic loci from which read was sequenced. 
 
Currently, the most popular read alignment tools for mammalian genomes are Bowtie2 149 and 
BWA150. Recent aligners such as Bowtie2, support gapped, local and pair-end alignments. 
Such aligners allow a settable number of mismatches in the reads. The preferred percentage 
for uniquely mapped reads reported by an aligner for ChIP-Seq data, although variable 
dependant on the organism, is typically above 70%147. Percentages lower than this, may 
suggest excessive PCR amplification and inadequate read or sequencing errors. High 
numbers of non-uniquely mapped reads may also suggest the ChIP’ed protein binds to 
repetitive DNA sequences, this can be circumvented by using PE sequencing or longer reads 
to reduce mapping ambiguity. However, most peak-calling algorithms tend to filter out multi-





Table 3-1: Short read alignment tools 
 
3.1.2.2.2  Alignment file processing: SAMtools 
The above-mentioned alignment tools typically generate genome alignments in various 
formats which can complicate downstream processing. Thus, in 2009 the Wellcome Trust 
Sanger Institute designed the Sequence Alignment/MAP (SAM) format which supports all 
sequence types an alignments, and the corresponding software package SAMtools155. The 
mandatory features in the SAM format are shown in (Table 5.3). SAMtools is a genomic library 
and software package that is used to manipulate and parse genomic alignments in the 
SAM/BAM formats (Tables 5.3-5.4). Features in SAMtools include, but are not limited to 
alignment format conversion, sorting and merging alignments, removing PCR duplicates and 
generating base pair position information, calling  SNPs as well as short indel variants. 
 
3.1.2.2.2  Peak calling  
An essential step in ChIP-Seq analysis is the detection of peaks from ChIPed regions, above 
background or input samples. Peak calling algorithms are used to identify regions of ChIP 
enrichment i.e. significant number of mapped reads at genomic region. This is arguably, the 







Source Extension Notes 
BWA150 MEM Exact Burrows- 
Wheeler 
transform 
BLAST-like Fast, efficient, based on Burrows- 
Wheeler transform 





Similar to BWA, part of suite of 
tools that includes TopHat and 





(k-mer based)  
Inexact Hash table or 
q-gram index 
Global Considers set of input variant 
alleles to 
better align to heterozygous sites 
SOAP2153 k-mer Inexact FM-index  BLAST-like k-mer inexact match seed; 
support at most 3 mismatches; 
GPU calculation supported 
Novoalign154 k-mer Inexact Hash table Global Similar to GSNAP and supports 
mismatches and gaps of up to 
50% of read length  
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packages have been developed; including MACS156, Phantompeakqualtools157, HOMER158, 
SPP157 (Table 3-4). Peak callers differ in their signal smoothing, background modelling and 
normalization methods. For point-source DBPs, peak callers such as SPP and MACS2 use 
cross-correlation shape based methods to model the strand-specific spatial distribution of 
reads and peaks are called when the distribution of mapped reads conforms to a probabilistic 
distribution around the binding site.  
 
3.1.2.2.2.1 Identifying ChIP-Seq enrichment  
ChIP-Seq binding site detection can be performed using one of three approaches; (1) Peak-
finding, (2) Peak-pairing or (3) Probabilistic binding detection (Figure 3-4)159.  
 
ChIP-Seq peak-finding analysis methods such as Model-based Analysis of ChIP-Seq 
(MACS)156 and SICER160 estimate a fragment size ( ), which is then used extend reads to 
represent the original ChIPed fragments. Approximately 1000 randomly sampled regions, with 
10- to 30-fold enrichment above genome background, are then used a model peaks.  
 
Using this peak model, MACS then slides a window size of  across the genome to identify 
regions that are significantly enriched relative to the genome background. Overlapping 
windows are then merged to form candidate peak regions. The Poisson distribution with 
dynamic parameter  for candidate peaks is then calculated and varies along the genome 
i.e. the  value for a specific locus is defined as: 
 
where, = constant estimated from genome background 
= constant estimated from the candidate region 
= constant estimated from an x-bp window centred at candidate region in control sample 
 
In most cases, the ChIP-Seq and control samples have different sequencing depths thus,  
MACS uses the relative difference (de novo normalizationto scale reads in both samples. In 
cases where control samples are unavailable,   is calculate from the ChIP-Seq sample 




Figure 3-3: Peak finding approaches159. a. Peak finding methods either 1. shift or extend ChIP-Seq tags locations 
in a 3’ direction by half the expected fragment length or equal to the expect fragment length, respectively. 2. 
Opposite tags are then merged to build unstranded tag density landscape which allows for the prediction of binding 
site locations based on the maximum tag density location. b. Peak-pairing methods 1. build similar, albeit stranded, 
tag density landscapes that neither shift or extend. 2. Peak maxima are predicted separately and 3. proximal peaks 
on opposite strands are paired and binding events are predicted from peak-pair mid-points. c. Probabilistic binding 
detection methods begin by 1. training by initial binding event location guesses, which are model how tags are 
expected to be distributed around “real” ChIP-Seq binding events. For every training step, each ChIP-Seq tag is 
probabilistically associated with proximal binding events that are 2. updated to fit associated tags and the binding 
model is updated to accommodate the accumulation of tags around all current binding events. 3. Steps 1 and 2 
are iterated and binding events with a low number of assigned tags are filtered out until the model converges to a 
final set of binding events. Purple circles represent predicted binding sites during peak finding. Green circles 
represent final and program output binding sites. 159 
 
-ment p-value to candidate peaks, which are then filtered by a p-value ≤ 10-5 threshold to 
determine final peaks. In the event that a control sample is available, for a particular p-value 
threshold, MACS calculates and thresholds peaks using the empirical FDR.  
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Peak-pairing analysis methods such as those used in GeneTrack161 and Model-based 
Analysis of ChIP-exo (MACE)162, build similar tag density landscapes to MACS, without 
shifting or extending tag locations. These algorithms determine peak locations on each strand 
separately. Nearby peaks in appropriate stranded orientations and within a given distance are 
then paired. While MACE functions by creating peak-pairs of closely spaced peaks on 
opposite strands, GeneTrack requires peaks to be paired manually. These algorithms then 
iterate the probabilistic assignments and update the binding event locations and model until 
the algorithm converges to a final set of binding locations, which are predicted from the peak-
pair midpoint (Figure 3-4).  
 
Peak detection analysis methods such as Genome Position Systems (GPS)163 and 
PeakSeq164 build probabilistic binding models. Initially, GPS summarizes the observed spatial 
read distributions from the control or input ChIP-Seq samples by assuming that every binding 
event will produce the same distribution of reads. This approach can only be used when an 
input or control sample is available. Next, GPS uses a probabilistic mixture model to assign  
binding event probability to the genome at single-base pair resolution. The number of reads 
assigned to a base by the mixture model is then used as a measure of relative strength of a 
predicted event at the base in question. Finally, GPS filters discovered events by comparing 
the number of reads at the predicted events to the corresponding normalized number of reads 
in the control/input sample (Figure 3-4). The statistical significance of the discovered events 
is then computed using a binomial distribution164, which is corrected for multiple hypothesis 
testing using the Benjamini-Hochberg procedure165.   
 
The peak calling algorithms (Table 3-4), use various statistical approaches to call and rank 
ChIPed peaks when comparing control/input and ChIPed samples. An intuitive and widely-
used linear normalization technique between ChIPed and control samples is based on 
sequencing depth. Using this scaling method, the number of reads within each sample is 
multiplied by a scale to make the total number of reads across samples the same or 
comparable.  Typically, the output of such algorithms produces and rank regions of enrichment 
based on absolute signal or computed significance of enrichment, P-values, q-values, fold 
enrichment  and/or FDRs, which can be influenced by the statistical model used, sequencing 




To assess for the reproducibility of reads and called peaks, the Pearson correlation coefficient 
of mapped read counts at each genomic position can be computed for each replicate. 
Replicate samples typically have a Pearson correlation >0.9 and values lower than 0.5 
suggest unrelated samples or one of the replicates may be of low quality. An informative 
measure of reproducibility can also be conducted using is the irreproducible discovery rate 
(IDR)166 which indicates the signal-to-noise ratio and assigns each signal a reproducibility 
index for each peak. IDR values >0.05 indicate consistent called peaks between replicates.  
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3.1.1.3 Differential binding Analysis tools  
Quantitative differential binding analysis be can be performed by comparing the read counts 
(e.g. DBChIP167, DEseq168, edgeR169,170) or read densities (MAnorm171) in peak regions 
between conditions. This approach provides a statistical assessment (p-value or q-value) of 
differential binding based on read-enrichment fold changes across conditions. Given the wide 
suite of tools available for differential binding analysis, selecting the right algorithm is largely 
determined by the datasets used as well as the biological question at hand. To assist in 
selecting the proper tool to use, based on the dataset, Steinhauser and colleagues published 
an informative decision tree172 (Figure 3.5). For the purposes of the analysis in this study, four 
differential binding tools are recommended (Figure 3-5, Table 3-5).  
 
3.1.1.1.1 DBChIP 
In the first step of analysis, DBChIP merges the lists of called peaks, obtained from external 
software such as MACS, from multiple conditions into a single consensus set. Called peaks 
are clustered using agglomerative hierarchical clustering with centroid linkage. The clustering 
approach ultimately begins by considering each object as a single-element cluster using 
linkage function, and at each iterative step two clusters that are similar are combined into 
larger clusters. The genomic positions of the consensus sites are then calculated, and 
weighted, as the average of the predicted or called peaks within each cluster. To detect 
differential binding sites, DBChIP tests a null hypothesis of non-differential binding at each 
consensus site. These tests are conducted through a generalized linear model with negative 
binomial distribution in order to account for the over-dispersion amongst samples.  
 
In the event that biological replicates are available, a Negative Binomial distribution is 
estimated by edgeR. This results in p-value, fold change estimates and user-specified FDR 
thresholds between samples for each site167. Although, it is possible to detect differential 
binding in the absence of biological replicates, the assumption that the background reads 
across ChIP samples is comparable can be incorporated into hypothesis testing. However, 
this is unlikely in most cases  and it is recommended that DBChIP be utilized for samples with 





ChIPComp, developed by the Wu lab,  extracts ChIP-Seq signals from different datasets by 
estimating and removing biological and technical artefacts through a generalized linear model 
with Poisson distribution 173. ChIPComp’s normalization approach assumes that the samples 
being compared have a non-trivial number of consensus peaks and that there are no global 
binding differences within the consensus peaks across all samples. Once consensus peaks 
are identified, ChIPComp performs the Wald’s test174 on log ChIP-Seq signals based on log 
read counts. The resulting p-values are then used as input for probability calculations of 
differential binding using a Bayesian approach173.  
 
3.1.1.1.3 MMDiff 
Unlike most differential binding tools which use read count enrichment strategies to detect 
differential peaks, MMDiff uses a kernel-based non-parametric strategy that focuses on 
changes in peak profile between samples175.  This approach is solely dependent on the spatial 
structure and features of the ChIP-peak, which allows for MMDiff to detect highly localized 
changes that alter the shape of the peak. Furthermore, this approach makes MMDiff highly 
robust towards normalization effects and independent of the signal-to-noise ratio. 
 
In MMDiff, each peak is treated as a distribution over a finite space, determined by the starting 
points of the reads within peaks. As these distributions are highly variable across the genome, 
the MMDiff developers utilize a machine learning kernel-based non-parametric test known the 
maximum mean discrepancy (MMD)176, to predict differential binding from the observed peak 
distributions. The MMD is defined as the largest difference in expectations of functions in the 
unit ball of reproducing kernel Hilbert space (RKHS)176. With this approach, peak distributions 
at the same loci in different biological replicates will be classified as more different than 
expected.  
 
To mitigate the effect of biological variability using this approach, for each peak, the number 
of reads mapping to that peak is averaged across all samples. Peaks are then binned based 
on the averaged read counts per peak. In each bin, the probability of observing an MMD value 
between the biological replicates in said bin is calculated. This probability is expected to be at 
least as large as the MMD value for a single peak between conditions. Obtained p-values are 
then corrected using the Benjamini-Hochberg method165 for multiple significance testing.  
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Notably, the approach applied by MMDiff requires multiple biological replicates in order to 
reliably estimate the variance between samples. Although MMDiff is able to detect changes in 
homotypic binding events, it has been recommended as a complementary analysis tool to 
count-based approaches for exhaustive differential analysis175.  
 
3.1.1.1.4 DiffBind 
Similar to ChIPComp, DiffBind creates a consensus set from called peaks, from which reads 
counted and subtracted from input/control datasets. Within DiffBind, RNA-Seq based 
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3.1.1.1.4.1 Trimmed Mean of M-values normalization (edgeR) 
The Trimmed Mean of M-values (TMM) normalization approach177 employed by edgeR uses 
raw sample data to estimate the appropriate scaling factors to be used in downstream analysis. 
TMM normalization uses an empirical strategy that equates the overall binding affinities of 
peaks between samples under the assumption that the majority of peaks are not differentially 
bound and that the total read count is dependent on a few highly enriched loci.  Thus, binding 
affinity log-fold changes can be reported as: 
 
and absolute intensity  are reported as: 
 
where  = observed count for samples, or  , in sample library,  
G= number of peaks 
N= number of samples in the experiment 
= normalization factor of sample library,  
= total number of reads for sample,   
 
The trimmed mean is the average after removing the upper and lower x% of the data, which 
is doubly trimmed by the log-fold changes of   and  . By default,   and 
 log fold changes are trimmed by 30% and 5%, respectively.  
 
The weighted mean of  is calculated as follows: 
 
where  represents the set of loci with valid and untrimmed  and   
= weighted mean  
 
The inverse variance approximation for   is  calculated using the delta method, which is 




Thus, the correction factor can be obtained by  
 
where all factors should multiple to one  
 
These normalization factors across multiple samples can be calculated by selecting one or 
more samples as a reference followed by the calculation of the TMM factor for each of non-
reference  sample/s. The calculated TMM factors can then be built into statistical models such 
as the Poisson distribution to test for differential binding in samples as compared to reference 
sample/s.  When the Poisson distribution model is used to detect differential binding, the  
observed library size is adjusted by a generalized linear model from a full library size to an 
effective library size.   A full library size represents the total number of reads within BAM files 
while the effective library size is described as the number of reads mapped within peaks.  
 
3.1.1.1.4.2 Relative Log Expression Normalization (DeSeq2) 
DeSeq2 uses a relative log expression (RLE) normalization168 approach that employs a 
geometric mean of raw read counts of the same locus in different samples. This strategy 
assumes that the read counts at a specific locus are proportional to DBP enrichment and 
sequencing depth. Similar to the TMM approach, by assuming that most loci are not 
differentially enriched, the median ratio  for a given sample is used as a correction factor for 
all read counts.  
 
where  = observed count for peak, in sample library,  
g= number of peaks 
N= number of samples in the experiment 




All samples in the experiment are then centred to the reference sample;  
 
The size or correction factor estimate , is the median of ratios or geometric mean of the -th 
samples read counts to those of a reference or pseudo-reference sample; 
 




3.1.1.4.1 Normalization for differential ChIP-Seq analysis 
Differential binding analysis involves quantitatively determining similarities and differences 
between samples using peak intensity. This approach requires read normalization between 
samples. A simple normalization approach is to scale reads using the total read number within 
the whole genome or within background regions. In this approach reads are scaled using a 
constant factor or using a locally weighted regression (LOESS)178. This assumes that 
differences in the mapped reads between samples are small enough to be compared to the 
total read number and the genome-wide read count distributions have equal means and 
variances across samples. These assumptions may not be valid in a majority of cases where 
the signal-to-noise ratio between samples differs. Thus, peak calling algorithms using this 
scaling method need to consider different signal-to-noise ratios. For example, MANorm uses 
this scaling method using a robust linear regression that is based on the MA plot171.  An MA 
plot is a scatter plot transformation of the M (log ratio) and A (mean average) scales between 
samples. ChIPComp, measures genomic background using the control sample and conducts 
a quantitative comparison of multiple ChIP samples which can also consider multiple-factor 




Recently, the spike-in approach was described to normalize ChIP-Seq experiments in a 
computational-independent manner. In this approach, a small amount of chromatin from the 
genome of a different species with close enough homology that the DBP of interest shares 
conserved epitopes is added to experimental chromatin179. The spike addition into the 
experimental chromatin which will be ChIP-sequenced is typically added before 
immunoprecipitation and functions as an internal control for each sample. As the number of 
reads obtained from the internal reference chromatin is the same across all tested samples, 
the spike can then be used as an internal control for read normalization. This approach allows 
for the detection of global differences in DBP enrichment to the genome of interest at an 
absolute level180. Spike-in analysis is particularly useful in cases where genome-wide peak 
distributions change drastically i.e. knockdown or stimulated samples.  
 
3.1.1.4.2 Signal-to-noise ratio  
The signal-to-noise (S/N) ratio is determined by the number and intensity of peaks identified 
in each ChIP sample. ENCODE uses two metrics to determine S/N; fraction of reads in peaks 
(FRiP) and cross-correlation profiles (CCPs).  
 
The fraction of reads in peaks (FRIP), positivity correlates with the number of peaks and the 
peak intensity of called peaks. The FRiP value is a simple ratio between the number of peaks 
( ) identified and non-redundant DNA fragments in the library ( ), calculated as; 
 
 
The FRiP value, can be used as a threshold to filter out ChIP samples where too few peaks 
detected. Notably, the FRiP value is largely dependent on the sequencing depth and peak 




The cross-correlation profiles (CCPs) metric measures the clustering of reads prior to peak 
calling and can be described by Pearson correlations. The Pearson correlation coefficient of 
mapped read counts at each genomic position can be computed for each replicate or sample. 
Pearson cross-correlations between map read densities in both the positive and negative 
strands are plotted on the y-axis with strand shifts on the x-axis. Ideally, a test sample should 
have high S/N ratio i.e. high fragment length ( ) and low read length ( ). Using the CCP 
approach, two quantitative metrics recommended by ENCODE can be scored;  
1. Normalized strand coefficient,  
2. Relative strand correlation,   
 
where, = minimum cross-correlation observed 
= fragment length 
= read length 
NSC and RSC scores can be calculated using phantompeakqualtools157  independently from 
peak calling. For sharp or point-source DBP peaks, ENCODE recommends an  
and an . Input and negative control samples on the other hand should have low 
NSC and RSC scores. A  large S/N ratio suggests that there is a high number of enriched 
regions within the genome however, there is no guarantee that the identified peaks are “true” 
binding sites. This means samples with high numbers of false positives may also have high a 
S/N. Thus, this approach has not been widely applied and is currently limited to a few species.   
 
3.1.1.2.2  Detection of motif binding sites with known PWMs 
Following the fulfilment of the main aim of this study to identify promoter-associated (PA) 
genomic loci with lower CTCF enrichment in CRC from ChIP-Seq data, the canonical CTCF 
motif position weight matrix (PWM), MA0139.1181,  can be used to scan these regions for “true”  
motif binding sites. The detection and annotation of motif binding sites with known PWMs can 




In general,  motif algorithms count the number of occurrences of each oligonucleotide of a 
given length in the ChIP’ed dataset which are compared with the number of occurrences that 
would occur by chance based on a background model. Background models are typically 
estimated form the composition of oligonucleotides within the ChIP’ed dataset. “True” binding 
sites typically have high probabilistic scores, i.e. p-value,  against the PWM of interest, while 
alternative or background sequences will have low PWM p-values. Known motif finding 
requires a p-value cut-off score to threshold matched PWMs, the determination of which is 
inversely proportional to the number of “true” binding sites with strong binding affinity.  
The p-value is represented as: 
 
Where,  
 = the set of motif sequences with cut-off, . 
 = the number of k-mer sequences, , with a PWM score  within a the 
set of regions, .  
 
The p-value is defined as the probability to observed at least the same number,  of motif 
instances with a cut-off,  in a random sequence with a total length equal the total length of 
sequences in a set of regions, 182. Notably, the occurrence of clustered binding motif sites, 
as observed in cis-regulatory modules (CRMS), leads to their over-representation.  However, 




3.1.1.4  Integrative chromatin signature analysis using genomic platforms  
The  PA-LCe sites discovered by this pipeline, were analysed and annotated using several 
web-based annotation/visualization tools described in Table 3-4.  
Table 3-4: Web-based annotation tools and browsers 
 
 
Web-based Tool Data analysed 
UCSC genome 
browser 
ChIP-Seq enhancer marks 




DNAse I Hypersensitivity peak clusters 
GeneHancer 
GNF Expression Atlas 2 
gnomAD v3 
GTEx 
lincRNA RNA-Seq reads 
NHGRI-EB GWAS catalogue 
PolyA Transcript Annotation 
Protein Interactions  
TCGA Pan-Cancer (COAD & READ) 
Transcription Factor clusters 
Vertebrate Conservation 
PrESSTo FANTOM5 Human Promoters 















With the above-mentioned considerations for ChIP-Seq analysis, several analysis pipelines 
have been developed largely in a context-specific manner. In this study, we sought to identify 
promoter regions with lower CTCF enrichment from ENCODE CTCF ChIP-Seq  data, in CRC 
cell lines as compared to normal colonic cells. This required a robust discovery pipeline that 
adhered to the ENCODE standards and practises as well as addresses the research question 
at hand.   
 
Figure legend in page 82   
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Figure 3-5: PA-LCe site discovery pipeline. The pipeline begins with a customized bioinformatic ChIP-Seq 
analysis workflow to identify Promoter Associated Lower-CTCF Enrichment sites (PA-LCes), containing the 
canonical MA0139.1 CTCF motif, in colorectal cancer lines as compared to wild type sigmoid colonic cells. 
Chromatin conformation capture (HiC) maps at the identified PA-LCes are then analysed to determine the 
chromatin contacts, loops and TADS at these genomic loci. Genomic loci analysis is then used to determine and 
annotate proximal gene and lncRNAs. Following which, CAGE and GTex database analysis is then used to 
determine the transcriptional status of annotated genes and lncRNAs within these genomic regions in colorectal 
cancer samples. Finally annotated chromatin marks within these genes are used to determine the epigenetic 
context of PA-LCes containing genomic loci.    
 
To do this, the PA-LCe site discovery pipeline must fulfil the criteria listed in Table 2.4. The 
PA-LCe CBS discovery pipeline used in this study is described in this section is shown on 
Figure 3-5. 
 
3.2.1 Dataset selection  
All ENCODE ChIP-Seq datasets in this study were downloaded from the NCBI SRA184. As the 
datasets in this study were obtained from multiple studies, in an attempt to reduce batch 
effects selected datasets contained matched input controls. Of the publicly available datasets 
available for each cell or tissue type were selected using the specific criteria (Table 3.5).  
 
3.2.2  ChIP-Seq Analysis methods 
3.2.2.1 Read processing 
3.2.2.1.1 FASTQCr: Quality control on raw reads 
Raw FASTQ files were quality checked using FASTQC-0.11.3to determine read quality 
metrics. FASTQC-0.11.3. The dataset criteria for subsequent analysis are listed in Table 3.5. 
Basic read information, including total number of reads, total unique reads, read length were 




Table 3-5: Dataset selection criteria and quality metrics 
 
3.2.2.1.1 Read mapping with bowtie2 
ChIP-Seq FASTQ files were aligned to GRCh38 human reference genome using default 
parameters in bowtie2. Default parameters in bowtie2 are as follows: 
 Input files: FASTQ 
 Read trimming: 0 
 Phred scores: Phred+33 quality  
 Reporting: report best alignments with MAPQ 
 End-to-end alignment: entire read must align with no clipping 
-D 15 : give up after 15 failed extends in arrow 
-R 2 : for reads with repetitive seeds, 2 sets of seeds attempted 
-N 0 : max number of mismatches in seed alignment= 0 
-L 22: length of seed substrings = 22 bp 
-i S,1,1.15: interval between seed substrings with respect to read length 
 
3.2.2.1.2 Post-alignment processing 
The aligned reads, in SAM file format, were sorted and converted into BAM files using 
samtools. Aligned and unique reads with MAPQ ≥ 30, were extracted using samtools from 
BAM files. In most well prepared ChIP-Seq experiments, most of the duplicated reads are 
likely to be “true” duplicates suggesting high levels of enrichment. Notably, the primary aim of 
this study is to identify differential, however marginal, CTCF enrichment sites. Thus, to avoid 
Species Human 
Read type SE or PE 
Sequencing depth >10 million reads 
Controls Required 
Replicate availability  Optional 
NRF Score 0.5≤  NRF ≥0.8 
GC content (%) >40% 
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decreasing signal strength and to identify regions with differential signal enrichment, duplicate 
reads in this study were not removed. Instead, duplicate reads were marked using Picard’s 
MarkDuplicates. The filtered reads were also indexed using samtools to produce .bai files.  
 
3.2.2.1.3 Quality control on processed reads 
Quality metrics for unprocessed, and processed BAM files were reviewed using FASTQCr. 
The aligned and processed reads underwent  quality control checks and were visualized using 
with FASTQC, IGV. 
 
3.2.2.2 Peak Calling  
Narrow peaks were called according to ENCODE ChIP-Seq guidelines using MACS2 with a 
p-value cutoff for peak detection set to 0.01 with the effective genome size set to “human” 
(2.7e9). Blacklisted regions were subtracted from narrow peaks that were called. Peaks in 
variable alternate scaffold loci and chrM (/chrM/d;/random/d;/alt/d;/chrUn/d) were also 
removed post peak calling using bedtools as well as the blacklist GRCh38 regions.  
 
3.2.2.3 ChIP-QC 
Quality control metrics on processed BAM files and corresponding narrowPeak files were 
computed using the ChIP-QC package in R. The main QC metrics on reads include; total 
number of reads in BAM file for each sample, the percentage of these reads that were 
successfully aligned to GRCh38  and the percentage of reads with a MAPQ ≥ 30. Using 
processed peak calls, ChIP-QC was used to compute peak-based metrics peak-based metrics, 
such as FRIP, peak profiles, and clustering.  
 
3.2.2.3 Differential binding analysis with DiffBind 
3.2.2.3.1  Dataset classifications 
In this study, ENCODE datasets from primary cell/tissue samples and cell lines were used. 
None of the datasets used in this study contained biological replicates, thus for the purposes 
of this analysis, biological replicates were defined as datasets from the same sample type. 
For the colonic datasets, the primary condition had two replicates (SColon 37 and 54) and 
CRC lines had 3 replicates (Caco2, DLD1 and HCT116). In order to verify the robustness of 
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the PA-LCe discovery pipeline in determining tissue-specific PA-LCes, we implemented the 
pipeline on a leukaemia dataset. This dataset, also obtained from ENCODE, included CTCF-
ChIP-Seq datasets of CD14+ monocytes and GM12878 were treated as biological replicates 
for the primary cells and lymphoblastic leukaemia cell line K562 was treated as the cancer 
line.  
 
3.2.2.3.2  Raw Peak Correlations  
Pearson correlations and Principal Component analysis on called peaks were conducted 
using the dba.plotheatmap and dba.plotPCA functions in DiffBind, respectively.   
 
3.2.2.3.3  Normalized Peak Correlations  
A binding matrix containing normalized scores based on the read counts per sample at every 
potential binding site was generated using the DiffBind dba.count function and used for 
subsequent differential analysis. Reads in CTCF binding site intervals were counted, scored 
and normalized using DeSeq2 in DiffBind185,186. DeSeq2 uses a read count based 
normalization strategy where the raw number of reads in the control sample is subtracted prior 
to the library size computation. The total number of reads in each dataset was used as the 
library size (bFullLibrarySize = TRUE). Pearson correlations and Principal Component 
analysis on normalized peaks was also conducted using the dba.plotheatmap  and 
dba.plotPCA functions in DiffBind  respectively.   
 
3.2.2.3.5  Differential binding analysis   
Read count correlations between datasets and conditions were calculated using a p-value 
threshold of 0.05. Differential binding analysis between the wild-type and cancer conditions 
was conducted with DESEQ2 using the full library size with an FDR < 0.05. All differentially 
binding conditions were saved as bed files for peaks with increased, decreased and non-
differentially bound CTCF peaks.  
 
Prior to differential binding analysis, contrasts were established to classify samples into 
condition groups i.e. primary and cancer conditions using the dba.contrast function. 
Differential binding analysis was executed using the core DiffBind function dba.analyze using 
DESeq2. This resulted in the assignment of p-values and FDR scores, to each candidate 
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binding site in order to indicate the confidence peaks identified were differentially bound. 
Visualizations of the differential binding analysis report including; Pearson correlation 
heatmaps, PCA, MA, scatter,  violin and boxplots were generated in DiffBind.  
 
Differential binding analysis data was extracted into data frames in RStudio as follows:  
1. Reduced Affinity binding peaks (db.loss),  
2. Increased Affinity binding peaks (db.gain)  
3. Stable differentially bound binding peaks (db.notdb)  
These data frames were also converted into bed and fasta files using bedr187 for subsequent 
analysis. 
 
3.2.2.4 Differential Peak annotations 
3.2.2.4.1  Chip annotations 
Differential binding data frames resulting from DiffBind were annotated using the 
ChIPpeakAnno package. A tag matrix for each data frame was generated and used to create 
tagHeatmaps and coverage plots of differentially bound sites 10kb around hg38 promoter 
regions. Other annotations and visualizations included; upset plots and Venn pie charts.  
 
3.2.2.5 Motif discovery using HOMER 
De novo motif discovery on bed file outputs was conducted using the HOMER188 
annotatePeaks tool in order to determine enriched motifs in differentially bound datasets. Motif 
discovery with HOMER was conducted on both the bed file and fasta outputs from Section 
2.2.2.4 to annotate differentially bound peaks with the canonical CTCF (MA0139.1181) motif. 
 
3.2.2.5 Promoter-associated lower CTCF-enrichment motifs  
The binding of CTCF to gene promoters has been shown to be a requirement for the adequate 
transcription of several tumor suppressors. Thus, LCe sites containing a canonical MA0139.1 
motif within promoter regions (PA-LCe sites) were extracted from annotated CTCF motif 
feature files.  
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 : PA-LCe sites in CRC are associated with 
enhancer-derived antisense long non-coding RNAs 
Human cancers are fundamentally heterogeneous with distinct subtypes associated with 
differences in genetic, molecular, cellular, pathological and clinical presentations. However, 
most cancer-related mutations occur in regions of the genome outside of genes.  However it 
difficult to determine which of these non-coding mutations have functional relevance in cancer 
and which are merely just noise. Although progressing, our limited understanding of how these 
non-coding regions regulate transcriptomic activity is still in its infancy. What has become 
increasing evident, is that the non-coding genome regulates the coding genome through 
multiple co-operative modes of action.  
 
Transcription of the human genome is proximity-dependent requiring chromatin contacts 
between promoters and other genomic loci, such as enhancers regions, and transcriptional 
machinery. The repertoire of contacts chromatin is engaged in at any given time is regulated 
by the three dimensional structure and organization of the chromatin. Indeed, aberrant 
contacts particularly between enhancer regions and cancer-specific genes i.e. oncogenes and 
tumor suppressors, that have been documented as drivers of oncogenesis. Classical 
examples include the acquired contact between the PDGFRA proto-oncogene and enhancer 
in the neighbouring TAD which results in the activation of PDGFRA in IDH-mutant gliomas16. 
Similarly, in lymphoblastic leukaemia tumors, the proto-oncogene Lmo2 is activated by the 
creation of new enhancer-promoter contacts17. In both these instances, the formation of 
ectopic cancer-specific enhancer-promoter contacts is facilitated by disruptions in CTCF-
mediated chromatin insulation. Mutations in CTCF binding sites have been frequently 
observed in multiple cancer tumors. In CRC specifically, the mutational profiles of CBs have 
been documented by several studies 77–79. Collectively, these studies have demonstrated 
dysregulated CTCF binding, either by somatic mutation or DNA methylation, as a putative 
oncogenic mechanism that results in cancer-specific chromatin contacts and thus altered 
transcriptional programs. Thus, CBSs with abrogated CTCF binding in cancer can be used as 
potential diagnostic and therapeutic markers. Promoter-resident CBSs functioning as 
“enhancer-docking sites” which regulate enhancer-promoter contacts, and transcriptional 
activation in a cancer and tissue-specific manner 88, have emerged as attractive targets.   
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In this study, we sought to identify and characterize promoter-associated CTCF binding sites 
with abrogated CTCF enrichment (PA-LCes) using ENCODE CTCF ChIP-Seq datasets. The 
full criterion of a PA-LCe site is in two parts:  
1. Lower CTCF enrichment in the cancer dataset as compared to primary/wild-type 
cells.  
2. The PA-LCe genomic region must be <1kb away from the closest annotated TSS in 
the hg38 human genome.”   
In order to address identify these PA-LCe sites, we sought to develop a straightforward and 
robust PA-LCe discovery pipeline with open-source tools (described in Chapter 3). 
Furthermore, we utilized various genetic and epigenetic platforms as well as studies to gain 





All ChIP-Seq data in CRC sample set was downloaded from the NCBI SRA184 using fastqdump.  
As the datasets in this study were obtained from multiple studies, in an attempt to reduce 
batch effects, the datasets selected had to contain matching input controls. ENCODE. CTCF 
ChIP-Seq datasets of primary sigmoid colon tissue and CRC cell lines were collected from 
NCBI SRA using fastq-dump.2.8.1. The full list of the  selected datasets falling within these 
criteria can be found in (Table 4-1).   
 







SColon54 HCT116 DLD-1 Caco-2 
Organism  Human 
Tissue Sigmoid Colon Colon 
Cancer type None Carcinoma 
 
Adreno-carcinoma 
Disease Anoxia -  Dukes' type C  
Cell Type Muscularis propria Epithelial 
Age 37 54 Adult 72 
Gender Male 
Data source Michael Snyder (Standford) Various labs 
Read type Paired-end Single 
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4.2.2. Bioinformatic pipeline 
The PA-LCe CTCF motif in CRC discovery pipeline developed (Chapter 3) conducted in this 
study is summarised in Figure 4-1 and Table 4.2.  
 
 
Figure 4-1: Differential ChIP-Seq analysis workflow and tools used to determine PA-LCe CTCF motifs in 
CRC. The workflow subjects each fastq file to a quality control and filteration step using FASTQC. Quality checked 
reads in fastq files are then mapped to the human genome with Bowtie2 and processed using samtools and picard. 
Narrow peaks are called from processed reads using MACS2. Called peaks are processed using bedtools. 
Differential peak analysis between called colorectal cancer (CRC) and wild type peaks is performed using DiffBind 
after undergoing quality control with ChIPQCr and IGV. Differentially called peaks are classified  into consensus 
peaks, lower and higher enrichment peaks within DiffBind. CTCF motif (MA0139.1) discovery is performed with 
homer on lower enrichment and primary consensus peaks which are then annotated to identify lower enrichment 
motifs in CRC cell lines as compared to primary colonic samples  
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4.3.1. PA-LCe Discovery in CRC  
4.3.1.1 Quality control: FASTQC 
Basic sequence statistics (total reads, total number of unique reads, the percentage of unique 
reads, the most abundant sequence, its frequency and the percentage of distinct uniquely 
mapping reads, read length, maxRead sequences, count and score) were determined using 
a custom bash script. 
The above-mentioned metrics were used to assess the datasets that would be used for 
subsequent analysis. All fastq files collected 4.1.1 underwent FASTQC analysis.  The full list 
of FASTQC results is shown in Section 5.2, an example of ideal FASTQC results (CTCF 
HCT116), is shown in Figure 4-1.  Samples not fulfilling the criteria in Table 3-4 were removed 





Figure 4-2: FASTQCr report of the CTCF  HCT116 processed BAM. Per base sequence quality,  Per tile 
sequence quality, Per sequence quality scores, Per base sequence content,  Per sequence GC content, Per base 
N content, Sequence length distribution, Sequence duplication levels, Overrepresented sequences, Adapter 






Legend in page 91. 
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4.3.1.2 Reading mapping and processing 
ChIP-Seq FASTQ files were aligned to GRCh38 human reference genome using default 
parameters in bowtie2 as described in 2.3.2.1. Unique and mapped reads with  MAPQ > 30 
were extracted for subsequent analysis using samtools.   
Duplicate reads were marked with picard MarkDuplicates. Resultant files were indexed using 
samtools. Filtered and unfiltered read files were analyzed using FASTQCr, the results can be 
found in Section 5.2. Raw and processed reads visualized on IGV (Figure 4-3).  
 
4.3.1.3 Peak calling 
Narrow peaks were called according to ENCODE’s ChIP-Seq guidelines using MACS2 with a 
p-value cutoff for peak detection set to 0.01 and the effective genome size set to “human” 
(2.7e9). Blacklisted regions (Table 6.3) and variable alternate scaffold loci were subtracted 
from called narrow peaks as described in 2.3.2.2. For visualized inspection of called peaks 
corresponding to mapped reads, BAM coverage, and read files along with corresponding peak 
calls from MACS2 were loaded onto IGV as seen in Figure 4-3.  
4.3.2  ChIP-QC 
Quality control metrics on processed BAM and corresponding narrowPeak files were 
computed using ChIP-QC in R. A summary of ChIP-QC results Table 4-2. The RelativeCC 
metric, which is calculated by comparing the maximum cross coverage peak to the cross 
coverage shift corresponding the read length for most datasets is greater than 1 indicating 
good enrichment and high quality datasets. Notably, the RelCC values for the primary dataset 
controls are almost 2-fold greater than that of the CTCF-ChIP’ed datasets. As seen in the 
code 4. Differential Peaks with DiffBind.Rmd,, the bAddCallerConsensus argument in 
ChIPQCr has been set to FALSE. If set to TRUE, ChIPQCr will generate a consensus peak 
set derived by merging all overlapping peaks in all provided peaksets, test and control alike, 
only keeping peaks that overlapping in at least two samples. This means, peaks found in only 
one library control will be excluded from subsequent differential binding analysis. For the 
purposes of this study this behaviour is not ideal has the removal of peaks found only within 
one library, specifically a control library, would be excluded and significantly reduce the 
number of differentially enriched sites obtained in this pipeline. Thus, to utilize all MACS2 
called peaks within each dataset, the bAddCallerConsensus argument was set to FALSE. This 
argument leads ChIP-QC to assume the replicate numbers of these peaks are missing as 
observed in Table 4-4.  
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The density of positions with different pileup values in primary CTCF-ChIP’ed datasets was 
greater than 1.5 indicating higher enrichment whereas SSD values for all CRC datasets were 
below 1 indicating an overall lower enrichment as compared to primary datasets. These SSD 
values correspond to the variance in sequencing depth across the different datasets. The 
signal-to-noise ratios of all the ChIP’ed datasets were greater than 5% indicating successful 
enrichment with no peaks mapped to blacklisted regions. Overall, the datasets used had 
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Table 4-2: Summary of CRC dataset ChIP-Seq filtering and quality metrics produced by ChIP-QC 
 
The processed reads for each of the datasets in this study passed the MAPQ filter as all 
aligned reads were filtered for reads with MAPQ vales ≥  30 (Section 2.3.2.1.2). As duplicated 
reads were not removed in this study, the percentage of duplicate reads in these datasets 
ranged from 0.41 to 30% with the highest duplication reported in both input and CTCF-ChIP’ed 
datasets.   
 
Table 4-3: Number and percentage of mapped, duplicated and MapQ filter passing reads 
 
All cross-coverage plots (Figure 4-3b) peak at a shift-size greater than  
and correlate to the fragment lengths reported in Table 4.2.  As shown in Figure 4-2c the 
coverage histogram, demonstrating the distribution of pileup values at each base pair, shows 
the primary datasets contain more CTCF enrichment as compared to the CRC datasets. This 
suggests that the CRC peaks have lower read densities in called peaks as compared to the 
primary dataset.  It is important to note that the higher CTCF-enrichment in the primary 
samples that are used as “controls” in this study may introduce bias in the analysis as prior to 
differential analysis, the data is skewed towards CRC lines containing peaks with lower read 









Figure 4-4: ChIPQC Results for CRC dataset. Top panel: Pearson Correlation plot of peak sets and Principal 
component analysis of peak sets. Centre panel: Log2 enrichment of read counts at specific genomic annotations; 
Bar plot of the percentage number of reads in peak; Density plot of the number of read counts in peaks; and Bar 
plot of the percentage of reads in blacklist, Bottom panel: Log2 base pairs of genome at differing read lengths; 
Cross Coverage score after successive strand shifts; and Plot of the average signal profile across peaks 
 
The ChIP efficiencies reported by the fraction of mapped reads (FRIP) for the colonic peaksets 
was relatively higher for CRC (15-30%) as compared to primary colon (<15%) (Figure 4-4). 
This suggests primary colon peaksets contained higher background as compared to CRC 
lines. However, the primary colon peakset contained a greater number of read counts within 
99 
 
called peaks as compared to the CRC lines, corresponding with the global reduction of read 
densities in peak regions observed in Figure 4-4. Peak profiles for all datasets were all centred 
and peaked around the summit regions in +/-200bp windows with the highest signal 
enrichment observed in primary colonic datasets, as well as the DLD1 dataset (Figure 4-4).  
The raw colonic peaksets are distinctly clustered by the condition; primary and CRC datasets 
respectively, as displayed by the Pearson correlation heatmaps and PCA plots (Figure 4-4).   
 
4.3.3 Normalization tests in the PA-LCe discovery pipeline 
 
As the datasets used in this here were obtained from various labs within the ENCODE 
Consortium, it was important to normalize the called peaks to obtain differentially CTCF 
binding. As recommended by the decision tree published by Steinhauser and colleagues 172, 
we used DiffBind to extract differentially enriched peaks between the primary and CRC 
datasets. Within DiffBind, we performed the normalization strategies using DeSeq2 and 
edgeR with either the full (total number of reads within BAM files) or effective (number of reads 
mapped within peaks) library size on ChIP-Seq read counts (Figure 4-5).  For this analysis 
the primary datasets were treated as replicates of a  reference sample that the CRC replicates 
were compared to and the false discovery rate for all normalization conditions was <0.05.   
 
The TMM normalization177 strategy employed by edgeR assumes that the majority of peaks 
between the primary and cancer samples are not differentially bound. This strategy also 
assumes that the total read count is dependent on a few highly enriched loci. Similar to 
edgeR’s TMM normalization approach, the relative log expression normalization168 strategy 
used by DeSeq2 assumes that most loci are not differentially enriched but also extends the 
edgeR approach by subtracting the scaled input/background read counts from the overlapping 
peaks. Unlike, the TMM normalization approach however, DeSeq2 assumes that the read 
counts at a specific locus is proportional to the enrichment of the DBP as well as the 






Figure 4-5: DiffBind normalization of CTCF ChIP-Seq read count data using edgeR and DeSeq2 with full 
and effective library sizes as displayed by MA plots. Dataset comparing colorectal cancer cell lines and primary 
sigmoidal colon cells. Each point represents a binding site, with pink points representing sites identified as 
differentially bound in colorectal cancer cell lines as compared to primary sigmoid colon cells (FDR <=0.05). Blue 
points  represent non-differentially bound sites between the two conditions. M-value on vertical axis and peak 
height A on the horizontal axis.  
 
Normalizing for library size, for both edgeR and DeSeq2 analysis methods, resulted in 
significant differences between the cancer (CRC) and primary datasets (Figure 4-5). In both 
the edgeR and DeSeq2 normalizations for both library size conditions, differentially enriched 
CTCF peaks were skewed towards sites with increased CTCF enrichment in CRC(Figure 4-
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5). The highest absolute log fold differences observed in the DeSeq2 full library size 
normalization condition as compared to sites with reduced CTCF enrichment (Figure 4-5).  
 
Biologically we expect a high number of differentially bound sites in CRC. Using edgeR we 
observed high numbers stable CTCF-enrichment peaks, 22 188 and 22 305 for effective and 
full library sizes, respectively (Figure 4-5). While DeSeq2 reported lower number of stably 
CTCF-enrichment peaks between conditions, 23 037 and 17 640 for the effective and full 
library sizes, respectively (Figure 4-5). Using edgeR analysed datasets we obtained 8 315 
and 8 098 differentially bound peaks using the effective and full library size, respectively 
(Figure 4-5). With DeSeq2 we observed a higher number of differentially bound peaks as 
compared to edgeR, with 12 144 and 33 511 differentially bound peaks using the effective and 
full library size, respectively. Thus, MA plots using DeSeq2 using the full library size revealed 
a large number of differentially enriched CTCF peaks in CRC (Figure 4-5) with the data 
skewed towards increased CTCF enrichment in the CRC dataset as compared to the primary 
dataset. This observation fulfils the biological expectation of obtaining a high number of 
differentially bound sites in the CRC condition. Furthermore, DeSeq2 further extends this 
assumption to subtract scaled/control reads from all overlapping peaks within the full library  
providing higher confidence in the differentially enriched peaks identified We opted to use the 




4.4 PA-LCe discovery pipeline reveals lower CTCF enrichment at as-lncRNAs 
promoters in CRC 
In this study, we hypothesized that sites with abrogated CTCF enrichment in CRC could be 
used as diagnostic and therapeutic markers for CRC. To this end, we developed a 
bioinformatic discovery pipeline to determine promoter-associated and differentially enriched 
CTCF motifs in CRC as compared to primary colonic tissue from ChIP-Seq datasets (Chapter 
3).  
 
Figure 4-6: PCA correlation analysis on the CRC dataset.  a. Raw ChIP peaks, and b. Read count normalized 
peaks.  
 
PCA correlation analysis of peaksets was conducted on raw called peaksets and normalized 
to read counts prior to differential analysis, which improved the correlations between the 
replicates within the primary and CRC peaksets, respectively (Figure 4-6). Read count 
normalization datasets were used for subsequent analyses. Correlation analysis using 
Pearson correlation co-efficient analysis showed a clustering of normal and cancer peaksets 
before and after relative log expression normalization (Figure 4-6a,b). All the CTCF sites 
obtained from the CRC dataset were plotted on heatmaps to visualize the distribution of CTCF 
sites within 2 and 10 kb from hg38 annotated TSS’ (Figure 4.7). Notably, the majority of CTCF 
sites within the CRC dataset are located proximal to TSS within the above-mentioned windows. 
Specifically, a majority of CTCF sites within these genomic ranges are located within genes 
(Figure 4-7) The distribution of these CTCF sites within these ranges is visually comparable 
to previous CTCF ChIP-Seq analysis studies revealing a majority CTCF sites located around 




Differential analysis of ChIP-Seq primary colon and CRC cell lines revealed 33 511 
differentially enriched CTCF peaks in CRC with only 152 (0.5%) displaying significantly lower 
CTCF enrichment (LCe) in CRC (FDR<=0.05) (Figure 4-8c).  Although, the most enriched 
motif (19.74%) in the LCe sites was the CTCF-like (CTCF-L/BORIS) motif (Table 6-9). 




















Figure 4-7: Heatmaps and vennpies of all CTCF sites in CRC dataset. Left panel. within 10kb window from 
transcriptional start site (TSS) and a vennpie depicting the location of  CTCF sites within this 10 kb window.  Right 
panel within 2 kb window around TSS and vennipie describing the locations of CTCF sites within the 2kb window 




The binding of CTCF to gene promoters validated in several examples, including at the 
promoter of tumor suppressor genes. Adequate transcriptional activity at these loci requires 
specific CTCF enrichment (Section 4.4.1). Genomic annotations of the LCe-CRC dataset 
described only 25 LCe sites located proximal (1 kb) to promoter-TSS’s (Figure 4-9). Only 4 
PA-LCe sites (5 motifs) were found to contain at least one canonical CTCF motif and were 
preferentially located proximal to (<10kb) antisense lncRNA loci (Table 4-6). Notably, the 
canonical CTCF site is considered indicative of CTCF binding in this ChIP-Seq dataset, 
however other variations in the genomic sequence of the CTCF motif (Section 1.3.2)68. These 
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Of the 3479 LCe peaks identified, 2648 (80%) were PA-LCes that, in general, were located at 
or proximal to bidirectional promoters expressing antisense lncRNAs with differential 
expression in CRC, including validated tumour-suppressive lncRNA, ZNF582-AS1. A pending 
question is whether these differences in CTCF binding are a consequence or a cause of the 
differential lncRNA expression observed in cancers. 
 
Figure 4-9: Distribution of CTCF sites in CRC dataset. Top panel: Heatmaps depict CTCF binding within 2kb 
of TSS as annotated by ChiPpeakAnno for a. stable, b. gained and c. lost CTCF sites in CRC as compared to 
primary sigmoid colon cells. Bottom panel: Vennpies annotating stable, lost and gained CTCF sites by their 
genomic location.  
CTCF binding at promoter regions has repeatedly been shown with 7-14% of silent promoter 
regions estimated to contain CTCF motifs189 and over 50% of active promoter regions 
containing CTCF motifs in multiple cell types97. Therefore, it is not surprising that the 
annotation of all the CTCF sites in the CRC dataset were located within 2kb of the hg38 TSSs 
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as displayed in heatmaps annotated by ChIPpeakAnno (Figure 4-7). Vennpies of differentially 
analysed CTCF sites; stable, gained and lost in CRC demonstrate the preference of CTCF 
binding site location to genic regions proximal to TSSs as compared to intergenic regions 
(Figure 4-9). Full genomic location annotations of all CTCF sites in each of these  datasets 





 Table 4-4: LC
e sites in C
R
C



























































































































































































































































































































































































































































































































4.4.1 PA-LCe as-lncRNAs as potential tumor suppressors 
4.4.1.1  PA-LCe at ZNF582-AS1 locus is a CRC meQTL 
According to the UCSC Genome Browser (GRCh38), the PA-LCe site at the chr19:56393010-
56393665 locus, is found at a bidirectional promoter which transcribes the ZNF582 gene as 
well as an antisense transcript ZNF582-AS1 (Figure 4-8). According to RNA-Seq, the 
ZNF582-AS1 transcript is enriched in the colon as well as ubiquitously expressed in all tissues 
from the Human Body Map lincRNAs190,191. Both ZNF582 and ZNF582-AS1 are upregulated 
in COAD192 (Figure 4-8). This PA-LCe CTCF motif, has CTCF ChIP-Seq peaks in both the 
transverse and sigmoid colon, which are lost in the Caco-2 and HCT116 cells (Figure 4-8). 
Furthermore, the PA-LCe CTCF motif is located within a CpG island, and DNAse I 
hypersensitivity peak cluster (95 cell types). This CTCF motif is located at a region displaying 
an active promoter histone signature in 7 ENCODE cell lines: high H3K27Ac, H3K4me3 and 
low H3K4me1. Intriguingly, this PA-LCe CTCF motif does not appear to contain COSMIC, 
TCGA or GWAS variants, however several variants have been annotated within the 2kb region 
surrounding this motif  (Figure 4-8). 
 
ZNF582-AS1 was identified as a target for epigenetic silencing in CRC using a lncRNA 
discovery pipeline that integrated H3K4me3 ChIP-Seq and reduced representation bisulphite 
sequencing (RRBS) data analysis193. In this study, the CpG islands within the ZNF582-AS1 
promoter and gene body were shown to be hypermethylated in CRC adenomas and cell lines 
as compared to normal colonic tissue, as well as others cancers193. RNA-Seq analysis 
revealed that although multiple ZNF582-AS1 variants were expressed in normal colonic tissue, 
the expression levels of all ZNF582-AS1 variants was significantly downregulated in CRC193.  
 
Similar expression and methylation patterns were observed for ZNF582 supporting previous 
data that identified the ZNF582 gene as a predicator of prognosis in cervical194, osophagael195, 
renal196 and colorectal cancer193. Furthermore, ectopic expression of ZNF582-AS1 
suppressed colony formation in CRC cell lines, RKO and SW480, but not HCT116 cells193. A 
recent differential expression analysis study also identified low expression of ZNF582-AS1 as 
a prognostic marker in renal cancer 196.  Together these findings suggest that ZNF582-AS1 is 

















likely affecting CTCF enrichment, can be used as a diagnostic and prognostic marker for 
multiple cancers. 
 
4.4.1.2  FGF13-AS1 is a tumor suppressor and prognostic marker 
The PA-LCe CTCF motif located at the chrX:138711873-138712449 locus is located within 
intron 1 of FGF13 and intron 1 of the antisense lncRNA FGF13-AS1(Figure 4-9). This CTCF 
motif is located within a DNAse I hypersensitivity cluster 25 bp downstream from a CpG island 
which is enriched for CTCF ChIP-Seq peaks in primary colonic tissue,  which are lost in Caco-
2 and HCT116 cell lines (Figure 4-9). Although proximal to an H3K27Ac peak in 7 ENCODE 
cell lines which aligns to the FGF13-AS1 locus, the motif itself is not enriched with H3K27Ac, 
H3K4me1 and H3K4me3 marks (Figure 4-9). Notably, the FGF13/FGF13-AS1 PA-LCe CTCF 
motif follows the directionality of the FGF13-AS1 gene (Figure 4-9).   
 
The FGF13 gene is upregulated in breast197, cervical198, prostate and colorectal cancer199. 
Notably, the FGF13 gene was found to be hypomethylated in prostate cancer200.  In CRC, 
post-transcriptional suppression of FGF13 by miR-10b, appears to suppress cell proliferation, 
migration and invasion in CRC cell lines199. FGF13 participates in a negative feedback loop 
with TP53 and FGF13 resident miR-504201. Specifically, p53 inhibits the transcription of  
FGF13 and miRNA 504201, which emanates from FGF13 intron 2, while miR504 binds directly 
to the 3’UTR of TP53 transcripts, inhibiting their expression in various cancers202.  In CRC 
tumors, FGF13 expression is downregulated as compared to normal colonic tissue (Figure 4-
9). Altogether this data suggests that FGF13  may function is a tumor suppressor.   
 
Recently, FGF13-AS1 has also been implicated as tumor suppressor whose expression is 
negatively correlated with patient prognosis in breast cancer203. Specifically, the 
overexpression of FGF13-AS1 in MDBA-MB-231 cells suppressed cell proliferation, colony 
formation, cellular migration and MYC expression and stability. In MCF7 cells, FGF13-AS1 
RNAi-mediated knockdown resulted in increased growth rates, invasion and migration, MYC 
expression and stability as well as  xenograft tumor sizes and lung metastatic nodes in mice 
models. This function is mediated by FGF13-AS1’s ability to repress glycolysis and the 
expression of stem cell markers OCT4 and SOX2 in MDBA-MB-231 cells203. Mechanistic 
assays including IGF2BP1 RNA immunoprecipitation (RIP), ChIP and RNAi suggest that 























binding proteins (IGF2BPs) preventing the interaction between MYC and IGF2BPs which in 
turn suppresses glycolysis and stemness in breast cancer203.  Furthermore, Ma and 
colleagues postulated that FGF13-AS1 participates in a negative feedback loop with MYC 
expression where MYC binding on FGF13-AS1 promoter prevents its transcription and binding 
to IGF2BP and thus promotes MYC-mediated oncogenesis203. Furthermore, PCAWG RNA-
Seq data shows that FGF13-AS1 is expressed in normal colonic tissue but not in CRC tumors 
(Figure 4.9) and cell lines (Figure 4-13). Altogether this suggests  FGF13-AS1 possesses 
tumor suppressive capabilities in various cancers.   
 
The opposing transcriptional expression and functionality of FGF13 and its antisense 
transcript, FGF13-AS1, in cancer suggests that the inhibition or progression of oncogenesis 
is dependent on which of the divergent transcripts arising from this promoter are upregulated. 
Intriguingly, the FGF13 gene body is hypomethylated in prostate cancer, providing a CTCF-
binding permissive landscape while in this study CTCF binding at the FGF13 promoter is 
reduced. It is tempting to speculate that methylation-dependent the binding of CTCF at this 
locus may function as the “switch” that favours FGF13, over FGF13-AS1, expression in cancer.  
 
4.4.1.3  FSIP2-AS2 (LOC101927196) as a potential tumor suppressor 
The FSIP2/FSIP2-AS2 locus contains two PA-LCe CTCF motifs separated by 91bp. These 
motifs emanate from intron 1 of FSIP2, intron 1 of FSIP2-AS1 and within the FSIP2-AS2 
promoter region. Both the antisense lncRNA transcripts, FSIP2-AS1 and FSIP2-AS2 are 
transcribed in the 3’-5’ direction while FSIP2 is transcribed in the 5’-3 direction. Both 
FSIP2/FSIP2-AS2 PA-LCe CTCF motifs share the directionality of the FSIP2 gene. The 
FSIP2/FSIP2-AS2 PA-LCe CTCF motifs emanate from within a CpG and DNAse I 
hypersensitivity peak cluster (Figure 4-10). Similar to the FGF13/FGF13-AS1 PA-LCe motif, 
these motifs are enriched with CTCF in primary colonic cells but not CRC cell lines and do not 
appear to have the H3K27Ac, H3K4me1 and H3K4me3 markers in 7 ENCODE cell lines 
(Figure 4-10). Unlike the FGF13/FGF13-AS1 PA-LCe motif, both the FSIP2/FSIP2-AS2 PA-
LCe CTCF motifs do not have COSMIC or TCGA mutations within >1kb of the CTCF motifs 





















FSIP2 (fibrous shealth interacting protein 2) is a protein typically associated with the sperm 
fibrous-sheath that plays a role in spermatogenesis. The FSIP2 gene is frequently mutated in 
metastatic breast carcinomas204 and myeloid plasmacytomas205 and has been presented as a 
“cancer driver” gene in breast intraepidermal adenocarcinomas206. Recurring amplifications at 
the FSIP2 gene have also been reported in testicular germ cell tumors207.  
 
To date, no studies have characterised FSIP-AS1 while the functionality of FSIP2-AS2 
(LOC101927196) has only been described in rat autism models. In this model, FSIP2-AS2 
was downregulated along with Gsk-3β and Trx2 while Fzd3, Wnt2, β-catenin, Bcl-2 and Bax 
were upregulated208. Notably these genes are involved in Wnt/β-catenin signalling and 
apoptotic pathways. Indeed, the FSIP2-AS2 overexpression in an autistic rat model lead to a 
decrease in cell proliferation and promotes apoptosis208. Thus,  the authors postulate that 
FSIP2-AS2 attenuates Wnt signalling by upregulating FZD3, which leads  to a decrease in β-
catenin phosphorylation. Notably, the overexpression of FSIP2-AS2 suppresses the oxidative 
stress response in these cells, as measured by 4-hyrosxy-2-nonenal,(4-HNE), reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) levels208. Although largely correlative, this 
data suggest that FSIP2-AS2 promotes apoptosis in a Wnt-signalling dependent manner. One 
can speculate that in the context of colorectal cancer, where FZD3 is frequently 
upregulated209,210, FSIP2-AS2 may function as a tumor suppressor.  
 
4.4.1.4  PA-LCe CTCF motif at oncogenic and tumor suppressive CIDEB/LBT4R2 
promoter 
The chr14:24310670-24311881 is the locus that did not appear to contain an annotated 
lncRNA within 10kb of the PA-LCe CTCF motif. This PA-LCe CTCF site is located within 
bidirectional promoter that transcribes LTB4R2 (Leukotriene B4 receptor 2) and CIDEB (Cell-
death-inducing DFFA-like Effector B) in the 5’-3’ and 3’-5’ directions,  respectively (Figure 4-
11). Like, most PA-LCe CTCF motifs discovered in this study, this promoter is located within, 
or near a CpG island and DNAse I hypersensitivity cluster (Figure 4-11). This CIDEB/LTB4R2 
PA-LCe CTCF motif appears to be enriched with H3K27Ac and H3K4me1 7 ENCODE cell 
lines (Figure 4-11). Although no COSIMC or TCGA mutations align with the CIDEB/LTB4R2, 





LTB4R2 has been proposed as a prognostic marker in triple-negative breast cancer211 and is 
frequently upregulated in oesophageal carcinomas where it contributes to malignant cell 
transformation212. Recently, LTB4R2 has been identified as a downstream target of the 
“cancer driver” KRAS pathway that mediates cell proliferation in KRAS mutant CRC cell lines 
LOVO and SW480213.  Other studies have implicated LTB4R2 in mediating several aspects of 
cancer progression including cell proliferation, survival and metastasis in bladder, breast, 
pancreatic and prostate cancer214–218. Ultimately, these studies demonstrate the significant 
role LTB4R2 plays in promoting oncogenesis.  
 
Intriguingly, the CIDEB promoter is hypermethylated in lung, colon, endometrial and breast 
cancers219–222 .The methylation status of the CIDEB promoter attenuates its transcriptional 
activity and has been correlated with poor patient prognosis in renal cell carcinomas220,223. It 
has been postulated that hypermethylation of the CIDEB promoter, and its downregulation, 
significantly contributes to the development of apoptosis resistance in cancer and is 
associated with poor patient prognosis 220,223. Together, this data suggests CIDEB play a role 
in suppressing tumorigenesis.  
 
Previous studies on this PA-LCe locus suggest that this bidirectional promoter transcribes 
both an oncogene (LTB4R2) and a tumor suppressor (CIDEB), and its expression is mediated 
by DNA methylation in a similar manner to the TP53/Wrap53 promoter. The opposing 
functionalities of the transcripts arising from this locus suggest that this PA-LCe, like the 
FGF13/FGF13-AS1 PA-LCe site, may function as a “cancer switch” where the progression or 
suppression of oncogenesis is dependent on which of the divergent transcripts emanating 
from the bidirectional promoter are upregulated. The mechanism that tilts the expression of 
this bidirectional promoter in either direction however, is currently unexplored.  
 
4.4.2 PA-LCe as-lncRNA genomic features 
Using multiple web-based genomic tools and browsers, we sought to characterize the defining 
features of the PA-LCe motifs discovered by our pipeline (Table 4-6). Like most CTCF motifs, 
all PA-LCe motifs were found within or proximal to; open chromatin (DNase I) hypersensitivity 
clusters, CpG islands (>300bp). However, PA-LCe CTCF motifs had varied histone marks in 



























Table 4-5: PA-LCe aslncRNAs in CRC 
 

















6236 7 2294 
chr19:56393010 
-56393665 
ZNF582-AS1 + 5436 0 1606 
chr: 138711873-
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PA-LCe CTC Motif ENCODE GRCh38 Epigenetic Features 
DNAse I  CpG  H3K27Ac H3K4me1 H3K4me3 
chr2:185738761 
-185739281 















Internal Proximal Low Low Low 
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4.4.3PA-LCe CTCF motifs in CRC are intra-TAD CTCF sites 
The PA-LCe CTCF motif discovery pipeline developed in this study revealed only intra-TAD 
CTCF motifs as annotated by Hi-C maps of HCT116 cells containing an inducible RAD21-
mAC vector prior to auxin induction95 (Figure 4-12).  Currently, no normal colon Hi-C data is 
available on the 3D genome browser, thus comparative chromatin contact visualization is not 
possible.  
 
Figure 4-14: Hi-C Maps of PA-LCe CTCF motifs in HCT116_RAD21-mAC_no_auxin at 40kb resolution95,224. 
a. ZNF582, b. FGF13-AS1, c. FSIP2-AS2, d. LBT4R2. Black lines represent PA-LCe sites. 
4.4.4.PA-LCe PCAWG RNA-SEQ  
The International Cancer Genome Project: Pan-Cancer Analysis of Whole Genomes RNA-
Seq data demonstrates a general trend of transcriptional downregulation with both PA-LCe  
 
Figure 4-15: International Cancer Genome project: Pan-Cancer Analysis of Whole Genomes (PCAWG) 
RNA-Seq data of PA-LCe genes and aslncRNAs 192.proximal genes and aslncRNAs in CRC as 
compared to normal sigmoid colon (Figure 4.13). In general, PA-LCes proximal to aslncRNAs 
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are not expressed in CRC while genes proximal to PA-LCes are expressed in primary sigmoid 
colon, albeit downregulated. Notably, FSIP2, FSIP2-AS2 and CIDEB data is not available in 
this database.  
 
4.5 Applying PA-LCe discovery pipeline using an ACC dataset 
In order to determine the versatility of the PA-LCe pipeline developed in this study to identify 
tissue-specific PA-LCes in cancer, we applied a myelogenous leukaemia (ACC) dataset onto 
the pipeline. A pipeline validation dataset consisting of an leukaemia dataset underwent the 
PA-LCe discovery pipeline developed in this study. The ENCODE CTCF ChIP-Seq datasets 
included primary CD14+ monocytes and the B cell derived cell line GM12878 as primary 
control biological replicates. In this instance, the two ACC cell line K562 replicates were used 
as the cancer dataset  (Table 6-3).  
 
Dataset quality control results produced by FASTQC and ChIP-QC are shown in Section 5.2.  
Unlike the CRC dataset, the leukaemia dataset contained only SE read datasets. As with the 
CRC dataset, all steps of the PA-LCe pipeline with intermediary results are reported in Section 
5.2. Similar to the CRC dataset PCA correlation analysis of peaksets was conducted on raw 
called peaksets and normalized to read counts prior to differential analysis, which improved 
the correlations between the replicates within the primary and ACC peaksets, respectively 
(Figure 4-13).   
 




For the ACC dataset the PA-LCe pipeline revealed 11 717 differentially enriched CTCF peaks 
between primary and cancer datasets, with 3479 peaks displaying significantly lower CTCF 
enrichment (FDR<=0.5) (Figure 4-13). Genome-motif analysis did not identify the canonical 
CTCF motif in the as one of the Top 8 enrichment motifs (Table 6-9), however the canonical 
CTCF motif was discovered in 80% (2648/3479) of the LCe peaks. Of these, only 160 sites 
were annotated as PA-LCe sites while 31 PA-LCe sites were closest to annotated ncRNA 
TSSs, 9 of which were annotated closest to as-lncRNAs such as CASP8 And FADD Like 
Apoptosis Regulator (CFLAR) Melanotransferrin (MELTF) genes (Section 5.2).  
 
 
Figure 4-17: Differentially bound CTCF peaks in primary CD14+ monocytes and GM12878  vs K562 cell 
lines. a. Raw ChIP-Seq Pearson correlation analysis of raw called peaksets. b. Relative log expression (DeSeq2) 
normalized called peaksets 
 
As with the PA-LCe sites discovered in the CRC dataset, the PA-LCe aslncRNAs in the ACC 
datasets shared similar genomic and epigenomic characteristics. Many of the as-lncRNAs 
discovered in this dataset have not been functionally characterized. Notably, some aslncRNAs 
like CFLAR-AS1 and Downregulated in Renal Carcinoma 3 (DIRC3) have been identified as 
prognostic markers for squamous cell225 and renal carcinomas226, respectively. Altogether, this 
data further reveals the applicability of the PA-LCe pipeline in identifying tissue-specific 
oncogenic aslncRNA loci with dysregulated CTCF binding in cancer which may be used as 
diagnostic and therapeutic markers.  
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 Conclusions and Perspectives  
 
This study presents a comprehensive ChIP-Seq analysis pipeline to identify promoter-
associated CTCF binding sites with differential, specifically abrogated, CTCF enrichment that 
may be hijacked by oncogenes in an attempt to favour cancer progression by modifying 
specific transcriptional programmes. Here we define protomer-associated lower CTCF-
enrichment CBSs as canonical CTCF motifs within <1kb from an annotated protomer-TSS 
with significantly reduced CTCF enrichment in the cancer cell line datasets as compared to 
the wild type/primary dataset. In this workflow, we identify promoter-associated lower-CTCF 
enrichment sites in colorectal cancer cell lines as compared to primary colonic tissue from 
CTCF ChIP-Seq data. We find that highly significant lower-CTCF enrichment sites, containing 
the canonical MA0139.1 CTCF motif 75,  are frequently proximal to bidirectional promoters of 
cancer-related genes and aslncRNAs.   
 
Several tools and pipelines exist for ChIP-Seq analysis some of which are extensively 
described in Chapter 3. The alignment of ChIP-Seq reads to reference genomes  is popularly 
conducted based on the Burrow-Wheeler transform employed by Bowtie2 and BWA. In this 
study, we utilized Bowtie2 for read alignments, which uses an inexact k-mer seeding strategy 
with a BLAST-like seed mapping approach (Table 3-1). ChIP-Seq peaks were then called with 
MACS2, a peak finding algorithm which uses a peak finding detection method that extends 
read tags in both the 5’ and 3’ direction before building a tag density landscape, using the 
maximum loci to predict DBP binding site locations (Figure 3-3). While several differential 
binding tools exist, in this study we followed differential binding analysis tool decision tree 
published by Steinhauser and colleagues 172 (Figure 3-4). In this study narrow CTCF peaks, 
with replicates from multiple ChIP-Seq experiments were classified as biological replicates 
with predefined region set. Thus, according to the Seinhauser et al. (2016) decision tree, we 
extensively reviewed ChIPComp, DBChIP, MMDiff and DiffBind  tools applicable to the 
datasets used in this study (Table 3-3).  
 
 Here we opted to used DiffBind as a differential analysis tool and employed a DeSeq2 relative 
log expression normalization approach. This strategy allowed us to incorporate information 
from all MACS2 called peaks fitted into a negative binomial distribution using FDR<0.05 as a 
significance threshold between the primary and cancer datasets. Indeed, according to the 
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Seinhauser et al. (2016) decision tree, multiple tools could have been employed in our analysis, 
however, all the forementioned differential binding tools excluding DiffBind are applicable only 
to sharp/narrow peaks. As such to ensure maximum applicability of this pipeline to different 
dataset types i.e. sharp and broad peaks, we opted to use DiffBind. Furthermore, both DeSeq2 
and edgeR normalization approaches can be used within DiffBind. This functionality allowed 
us to compare each of these normalization approaches with both the full and effective library 
sizes. Biologically, the number of differentially enriched CTCF sites between the primary and 
cancer conditions is expected to be high i.e. the number of stable/unchanged CTCF sites is 
low. This expectation was observed using the DeSeq2 normalization approach which as 
compared to edgeR, extends this assumption to subtract scaled control/background read 
counts from overlapping peaks (Figure 4-5). Thus, when using the full library size, which 
includes a greater proportion of these control reads by virtue of including all reads in bam files, 
DeSeq2 is able to more stringently identify high-confidence differential enrichment sites 
between conditions. As such the number of differentially enriched CTCF sites identified by the 
full library size are significantly lower than those identified using the effective library size 
(Figure 4-5, Section 4.3.3) fulfilling the biologically expectation. This strategy was effective in 
addressing research question posed in this study while attempting to control for the ChIP-Seq 
datasets obtained from varied experiments. The tools discussed here are by no means 
exhaustive and  must be extensively reviewed in the context of the research question at hand.  
 
Somatic mutations at CTCF sites can result in differential CTCF binding. However, 
redundancies at specific bases within the CTCF motif can mean some genomic mutations at 
CTCF motifs do not alter CTCF binding. Furthermore, varied  combinations of mutations within 
the same motif can disproportionately affect CTCF binding at that genomic locus. Thus, while 
WGS approaches have been used to identify cancer driving CTCF motifs at base-pair 
resolution, these mutations cannot be fully prescriptive of differential CTCF binding and 
require the CTCF enrichment data availed by epigenetic-based analysis such as ChIP-Seq or 
ChIP-Exo. Previous strategies consisted of whole genome sequencing or association 
approaches to identify overrepresented mutational sequences by mutation calling followed by 
CTCF motif scanning at identified loci. Indeed these approaches have identified mutational 
hotspots in gastric77 and colorectal cancers78. Additionally, while preparing this manuscript, a 
computational method CNCDriver was developed. This WGS-based approach identified 
CTCF mutational insulator driver sites in 1962 genomes in various cancers, including CRC227. 
The validation of CNCDriver discovered CTCF  insulator sites, validated by CTCF ChIP-Seq, 
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3C and CRISPR-Cas9 and suggested that CTCF insulator sites function as putative oncogenic 
drivers 227.  
 
GWAS approaches have also been previously employed identify CTCF-dependent CRC-
specific driver mutations. For example the 1000G imputation and meta-analysis of 5 GWAS 
studies representing over 7000 CRC genomes identified 3 new susceptibility loci for CRC, 
with the second strongest association linked to the uncharacterised intergenic lncRNA, RP11-
58A18.1228 while a combinatorial GWAS,  in situ promoter capture Hi-C (CHi-C), RNA-Seq 
and ChIP-Seq analysis approach in 34 627 CRC cases identified 31 new CRC risk loci 
primarily located at enhancer and promoter regions229. In this study using a DeSeq2 relative 
log expression normalization approach with the full read count library size of MACS2 called 
peaks, we identified 33 511 differentially enriched CTCF sites in CRC cell lines as compared 
to primary sigmoidal colon cells. Of these, we identified of 14 CRC-specific LCe canonical 
CTCF motifs and  4 PA-LCe sites. While this approach is evidenced by differential CTCF 
enrichment identified from ChIP-Seq data, the mutational status of these sites was not 
analysed and therefore cannot be assumed to be the underlying mechanism driving differential 
CTCF binding in these datasets as the susceptibility loci identified using WGS or GWAS 
approaches. Unlike ChIP-Seq datasets, WGS and GWAS datasets tend to have limited 
accessibility and typically rely on bespoke experimental datasets. Thus, to mitigate each of 
these limitations, our approach sought to use publicly available ChIP-Seq datasets to identify 
differentially enriched CTCF binding loci in CRC cells, that specifically aimed to identify 
reduced binding of CTCF at promoter-associated sites.  
 
The comprehensive pipeline developed in this study takes as input ENCODE ChIP-Seq 
FASTQ datasets, discovers differentially enriched CTCF peaks with DeSeq2 in DiffBind and 
determines the promoter-associated CTCF motifs within these peaks. It is important to note 
that the DeSeq2 normalization strategy using the total library size does not attempt to control 
for technical bias in the pull-down efficiency of the ChIP-Seq experiments nor the likely varied 
antibodies used in each dataset. One caveat to our pipeline is that the collection  ChIP-Seq 
datasets from various labs likely introduced technical variations compounded by the intrinsic 
variabilities in the ChIP-Seq protocol. This necessitates the requirement of robust 
normalization strategies. The integration of normalization methods to comparative ChIP-Seq 
analysis tools has become widely standardized, although several strategies exist. Here, we 
employ a relative log expression normalization strategy168 with DeSeq2 implemented in 
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DiffBind186 in pre-processed datasets. Multiple normalization strategies for RNA-Seq data 
have been developed to control of multiple dataset usage,  however, the comparison of ChIP-
Seq data is complicated by the different background noises, signal-to-noise ratios and 
antibody types in distinct experiments. Unfortunately, while extensive normalization strategies 
have been integrated into this pipeline, these biases cannot be fully mitigated when using 
datasets from different experiments. Several attempts to control for such biases have been 
conducted in the prior art including differential enrichment strategies employed by tools such 
as ChiPComp173  however, this inherent caveat of ChIP-Seq analysis has not been fully 
mitigated to date. For the purposes of the research question addressed in this study, we 
sought to use DeSeq2’s relative log expression normalization strategy168  as it incorporates 
information from all peaks in each experiment to estimate a common dispersion parameter, is 
robust and allows for arbitrary mean-variance relationships allowing it to be highly adaptive to 
the different datasets (Table 3-3) used in this study.  
 
In this pipeline, the ChIP-Seq peaks used for differential analysis are required to be called by 
MACS2 in more than one dataset i.e. only consensus peaks in the Sigmoid 37 and Sigmoid 
54 dataset were used as control peaks while in the CRC cell lines, peaks were used for 
differential enrichment analysis only if said peak was identified in at least two datasets. This 
absolute requirement for multiple datasets per condition treated effectively as replicates for 
each condition in this pipeline may, albeit to a low extent, control for these artefacts. Thus, this 
pipeline can only be used for the differential analyses of ENCODE ChIP-Seq datasets with at 
least two biological replicates in two conditions (wild type and cancer) to discover known motifs 
with differential ChIP’ed DBP enrichment. This approach prevents, to a certain degree, false 
positives from being mis-interpreted as differentially enriched peaks, and further increases the 
stringency of this pipeline when identifying differentially enriched CTCF sites. Furthermore, 
the comparative sequencing depths of the datasets used in this study increased our 
confidence in the binding site discovery between these samples.  
 
The  PA-LCe discovery pipeline developed in this study resulted in some previously validated 
CTCF binding sites correlated with oncogenic activity. Intriguingly, the PA-LCe sites identified 
in this study emanate from bidirectional promoters whose differential methylation patterns in 
cancer have been previously described by others193. Genomic annotation analysis of the PA-
LCe sites identified by this pipeline, revealed a subset of PA-LCes described as bidirectionally 
transcribed promoters whose antisense transcripts are lnRNAs. A survey of the literature 
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further implicates these aslncRNA PAL-Ces in oncogenesis (Section 4.4) . A notable example 
is the PA-LCe site identified in the promoter of tumour-suppressive aslncRNA ZNF582-AS1 
192. The functionality of ZNF582-AS1 in CRC was previously discovered and described by 
bioinformatic pipeline that integrated RNA-Seq, ChIP-Seq and RRBS data in CRC tumors and 
cell lines in order  to identify lncRNAs silenced by DNA methylation in CRC193. This data further 
strengthens the precision and robustness of which this PA-LCe discovery pipeline developed 
here. Coupled to these analyses, the discovery of cancer- and tissue-specific enhancer 
“docking-sites” promoter-proximal CTCF sites at oncogenes in various cancer cell lines by 
Richard Young’s group, implicates PA-LCes as cancer-targets that elicit a therapeutic 
vulnerability85. Altogether, these studies further substantiate the relevance and usefulness of 
the PA-LCe CTCF discovery pipeline developed in this study in identifying potential oncogenic 
drivers.  
 
The PA-LCe pipeline is applicable to multiple cellular contexts and can be used to identify 
candidate PA-LCe sites. In support of this, we used CTCF ChIP-Seq ACC cell lines and 
primary CD14+ monocytes and GM12878 to determine the applicability the PA-LCe pipeline 
developed in this study.  Applying the developed PA-LCe pipeline to ChIP-Seq leukaemia 
datasets revealed similar genomic characteristics and antisense-lncRNAs to those identified 
in CRC. Together, this data reveals a potential mechanism in which CTCF enrichment at the 
promoters of cancer-targeted genes and/or aslncRNAs are targeted in cancer cells in order to 
promote oncogenesis.  
 
The PA-LCe sites identified in this pipeline represent regions of differential epigenetic state, 
specifically CTCF binding. Whether the differential binding of CTCF at these loci is directly 
linked to the mutational status of the PA-LCe sties is yet to be determined.  Future work will 
include the validation of these PA-LCe sites in matched normal versus tumor samples to 
determine the mutational status of PA-LCe sites in cancer using assays such as 3C, RRBS, 
Capture-C, CRISPR-Cas9 and the bacterial one-hybrid assay. Given the partially documented 
methylation status of PA-LCe sites from previous studies193, it would be interesting to 
determine the effect of DNA methylation on these PA-LCe sites, which can be assayed using  
RRBS and/or reprogrammable CRISPR-mediated site-specific DNA methylation. Surveillance 
of RNA-Seq and CAGE datasets including FANTOM5,  has shown that a majority of the PA-
LCe proximal aslncRNAs are downregulated in CRC tumors. It would be interesting to 
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determine whether the expression of these aslncRNAs is directly linked to CTCF binding at 
their promoter regions within the same sample.  
 
Recent studies implicating the formation of CTCF-lncRNA complexes at promoter regions as 
a mechanism of regulating CTCF docking on chromatin and subsequently promoter activity. 
From our data, this opens up the question on whether aslncRNAs at PA-LCe loci may be 
molecular targets for the regulation of CTCF binding and transcriptional activity in cancer. The 
discovery of aslncRNAs at the PA-LCe sites adds to the growing body of evidence that the 
non-coding genome regulates coding genome through multiple co-operative modes of action. 
It will be intriguing to determine whether the decrease in CTCF enrichment at PA-LCes is 





Table 6-1: CRC Datasets 



















Table 6-2: Leukaemia dataset 













Table 6-3: List of tools used in PA-LCe discovery pipeline  
GNU bash v5.0.2(1) 
 macs2 v2.1.2 
 bedtools v2.27.1 
 IGV v2.3.86 
 homer v3.4 
 fastq-dump v.2 
 fastq v0.11.3 
 bowtie2 v2.2.6 
 samtools v1.2 
 picard-2.21.3-0 
R v3.5.1  
 pyranges v1.2.0 
 Rsamtools v1,34.1 
 rtracklayer v1.42.2 
 rgl v0.100.30 
 Tmisc v0.1.22 
 DiffBind v2.10.0 
 matrixStats v0.55.0 
 ReactomePA v1.26.0 
 VennDiagram v1.6.2.0 
 XVector v0.22.0 
 BiocParallel v2.10.0 
 AnnotationDbi v1.44.0 
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 GenomeInfoDb v1.18.2 
 stats4 v3.5.1 
 stats v3.5.1 
 utils v3.5.1 
 bedr v1.0.7 
 edgeR v3.24.3 
 plot3Drgl v1.0.1 
 ChIPQC v1.18.2 
 ggplot2 v3.2.1 
 SummarizedExperiment v1.12.0 
 biomaRt v2.50.2 
 org.Hs.eg.db v3.70 
 futile.logger v1.4.3 
 Grid v3.5.1 
 TxDb.Hsapiens.UCSC.hg38.knownGene’ v3.4.0 
 Biobase v2.42.0 
 IRanges v2.16.0 
 BiocGenerics v0.28.0 
 graphics v3.5.1 
 datasets v3.5.1 
 rstudioapi v0.10 
 limma v3.38.3 
 plot3D v1.3 
 RColorBrewer v1.1-2 
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 DeSeq2 v1.22.2 
 DelayedArray v0.8.0 
 clusterProfiler v3.10.1 
 ChIPpeakAnno v3.16.1 
 ChIPSeeker v1.18.0 
 GenomicFeatures v1.34.8 
 GenomicRanges v1.34.0 
 S4Vectors v0.20.1 
 parallel v3.5.1 
 grDevices v3.5.1 
 methods v3.51 






Table 6-4: FASTQC Quality Metrics 
Quality Metric Threshold  
Per base sequence quality  Lower quartile for any base must be more than 5  
Per tile sequence quality Any tile must show a mean Phred score less than 5, less than the 
mean for that base across all tile 
 
Per sequence quality scores The most frequently observed mean quality must be above  20 (1% 
error rate) 
Per base sequence content The difference between A and T, or G and C must be less than 
20% in any position 
 
Per base GC content The sum of the deviations from the normal distribution  must 
represent  less than 30% of the reads. 
Per base N content Any position must show an N content of  less than 20% 
 
Sequence length distribution Sequences must be the same length that is greater than 0bp 
Sequence duplication levels Non-unique sequences must make up less than 50% of the total. 
 
Overrepresented sequences Any sequence must represent less than 1% of total 






Table 6-5 SAM File Format 
Columns Description 
QNAME Read name 
FLAG SAM flag 
RNAME Contig name or * for unmapped reads 
POS Mapped position of base q of a read on the reference sequence 
MAPQ Mapping quality 
CIGAR CIGAR string describing insertions and deletions 
RNEXT Name of mate 
PNEXT Position of mate 
TLEN Template length 
SEQ Read sequence 
QUAL Read quality 





Table 6-6: BAM File Format 
Columns Description 
Magic BAM magic string 
l_text Length of header text 
Text Plain header text in SAM 
N_ref Number of reference sequences 
L_name Length of the reference name 
Name Refence sequence name 
I_ref Length of refence sequence 
Block_size Total length of alignment record, excluding this field 
refID Refence sequence ID, -1 for unmapped reads 
pos Length of read name POS 
L_read_name Length of read name QNAME 
Mapq Mapping quality MAPQ 
Bin BAI index bin 
N_cigar_op Number of operations in CIGAR 
Flag Bitwise flags FLAG 
L_seq Length of SEQ 
Next_refID Ref-ID for next segment  
Next_pos 0-based leftmost pos of the next segment 
Tlen Template length TLEN 
Read_name Read name 
Cigar CIGA string 
Seq Read sequence 
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Qual Phred-scaled base qualities 
Tag Two-character tag 
Val_type Value type 
value Tag value 
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chrom Required name of the chromosome or scaffold. Any valid seq_region_name can be used, 
and chromosome names can be given with or without the 'chr' prefix 
chromStart  start position of feature in standard chromosomal coordinates (i.e. first base is 0) 
chromEND position of feature in standard chromosomal coordinates 
name Optional  sequence label  
score a score between 0-1000 
strand defined as + (forward)  and – (reverse) 
thickStart coordinate at which to start drawing the feature as a solid rectangle 
ThickEnd coordinate at which to stop drawing the feature as a solid rectangle 
itemRgb an RGB colour value (e.g. 0,0,255). Only used if there is a track line with the 
value of itemRgb set to "on" 
blockCount the number of sub-elements (e.g. exons or SNPS) within the feature 
blockSizes the size of sub-elements displayed in blockCount 





Table 6-8: General Feature Format (GFF) or General Transfer Format (GTF) 
Field Description 
seqname name of the chromosome or scaffold (Ensembl identifier); chromosome names can be given 
with or without the 'chr' prefix 
source name of the program that generated this feature, or the data source 
feature feature type name, e.g. Gene, Variation, Similarity 
start start position of the feature, with sequence numbering starting at 1 
end end position of the feature, with sequence numbering starting at 1 
score a floating point value 
 defined as + (forward) or - (reverse) 
frame one of '0', '1' or '2'. '0' indicates that the first base of the feature is the first base of a codon, '1' 
that the second base is the first base of a codon, and so on. 
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